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The modulation of voltage dependent calcium channels (CaV) by CaM has emerged as an important paradigm for understanding general CaM modulatory processes in biology. The prevailitng idea for CaM regulation of CaV channels has been the IQ-centric hypothesis. By combining scanning alanine mutagenesis and FRET 2-hybrid binding assays, the IQ-centric model is challenged. An alternative model whereby CaM departs from the IQ domain is described. By applying the same methodology to naturally occurring RNA edited variants of CaV1.3 channels, a surprising role for apoCaM modulation of CDI is discovered. This apoCaM modulation is then generalized to support a mechanism of tuning of calcium flux into brain cells via ambient fluctuations in CaM. The tuning mechanism is positioned for more general study by developing a novel genetically encoded sensor of calcineurin (CN) activation, CN being the dominant CaM-activated phosphatase throughout biology. By deploying the sensor in neonatal and acutely isolated adult cardiac myocytes, it is observed that CN is capable of being activated in response to single twitch calcium transients in neonatal but not in adult myocytes. The underlying mechanism for the differential CN activation in neonatal and adult myocytes is investigated with a mathematical model capable of fitting the cardiomyocyte sensor data at all experimentally investigated pacing frequencies (0.1Hz-1Hz). Our experimentally-based mathematical model identified free CaM concentration as the main parameter responsible for determining the amplitude and kinetics of CN response in neonatal and adult cardiomyocytes. The tuning conjecture of CaM for the function of both CaV1.3 and CN looms as a potentially central feature of Ca2+ signaling in brain and heart.
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 Chapter 1 

Tuning of CaV 1.3 Calcium Channels by CaM


1.1 Introduction and Background​[1]​










Upon channel opening calcium ions enter the cell and bind the resident calcium sensor CaM.  Ca2+/CaM-channel complex then induces conformational changes that enhance channel opening (positive feedback or channel facilitation) in some channel types  ADDIN EN.CITE (; ) , and inactivate (negative feedback or inactivation) the channel in others  ADDIN EN.CITE (; ).  Remarkably, binding of Ca2+ ions to individual C- and N-lobes of CaM results in alternate forms of channel regulation  ADDIN EN.CITE (; ; ).  The C lobe of CaM responds to rapidly fluctuating calcium signals near the mouth of the channel (local Ca selectivity) while the N lobe of CaM detectc slowly varying global calcium concentration changes (global selectivity)  ADDIN EN.CITE (; ; ; ; ).  Many biological functions including the stability of cardiac action potential are influenced by this CaM dependent calcium feedback regulation and are proposed to be targets for therapeutic treatment and management of cardiac arrhythmias  ADDIN EN.CITE (; ; ; ; ; ).  
 The currently accepted conceptual framework for understanding calcium induced conformational changes leading to concrete functional effects is shown in Fig. 1.2. This schematic model summarizes the states traversed from the opening of the channel to the final inactivation or facilitation with a specific reference to L-type CaV1.3 channels.  Channels in state E lack pre-associated CaM. They open normally in response to voltage depolarization pulses from the holding potential of  –80mV (baseline), but fail to undergo Ca2+/CaM dependent inactivation (CDI) over the typical depolarizing pulse of duration ~300 ms  ADDIN EN.CITE ().  Pre-association of apoCaM to the channel results in state A. The channels in this state open normally and can also undergo CDI. The bulk cellular apoCaM can not easily access the ‘naked’ channels (channels with no apoCaM), and switching between states E and A is very slow occurring in 10s of seconds (). There also exists signal bifurcation between the two lobes of CaM. Binding of Ca2+ ions to the C-lobe results in C-lobe inactivation state IC; while, the binding to the N- lobe induces N-lobe current inactivation and pushes the channels into the state IN. 

Figure 1.2 General scheme for CaM regulation of the representative L-type CaV1.3 channels. (a) Primary configurations of CaM/channel complex with respect to CaM-regulatory phenomena (E, A, IC,IN and ICN). Inset at far right, cartoon of main channel landmarks involved in CaM regulation, with only the pore-forming α1D subunit of CaV1.3 diagrammed. Ca2+-inactivation (CI) region, in the proximal channel C terminus (~160 amino acids (aa)), contains elements potentially involved in CaM regulation. IQ domain (IQ), comprising the C-terminal ~30 aa of the CI segment, long proposed as preeminent for CaM/channel binding. Dual vestigial EF-hand (EF) motifs span the proximal ~100 aa of the CI module; these have been proposed to play a transduction role in channel regulation. Proximal CI (PCI) region constitutes the CI element exclusive of the IQ domain. NSCaTE on channel N terminus of CaV1.2–1.3 channels may be the N-lobe Ca2+/CaM effector site. (b) Whole-cell CaV1.3 currents expressed in HEK293 cell, demonstrating CDI in the presence of endogenous CaM only. CDI observed here can reflect properties of the entire system diagrammed in a, as schematized by the stick-figure diagram at the bottom of b. Here and throughout, the vertical scale bar pertains to 0.2 nA of Ca2+ current (black); and the Ba2+ current (gray) has been scaled ~3-fold downward to aid comparison of decay kinetics, here and throughout. Horizontal scale bar, 100 ms. (c) Currents during overexpression of CaM WT, isolating the behavior of the diamond-shaped subsystem at bottom. (d) Currents during overexpression of CaM12, isolating C-lobe form of CDI. (e) Currents during overexpression of CaM34 isolating N-lobe form of CDI. (c–e) Vertical bar, 0.2 nA Ca2+current. Timebase as in b.

In the presence of wild-type CaM (CaMWT) channels can enter fully inactivated state ICN with strongly reduced opening  ADDIN EN.CITE (; ) (current trace in Fig. 1.2b). Moreover, entry into ICN state likely involves cooperative interactions between the C- and  N-lobe of CaM modeled  by parameter λ. Note also that as a result of high level of cooperativity in binding of Ca2+ ions within each lobe of CaM, the model in Fig. 1.2a excludes the binding of  single Ca​​​2+ ion to CaM (). Further, only a single CaM is included in the schematic model based on previous observations  ADDIN EN.CITE (; ). The currently held dominant structural basis for the state model of Fig. 1.2a is the IQ centric hypothesis (). According to this view, the IQ domain (Fig. 1.1) serves as not only the apoCaM preassociation site, but also as the effector site for CDI transduced by Ca2+/CaM  ADDIN EN.CITE (; ; ). The IQ centric paradigm has motivated several groups to solve the crystal structure of  Ca2+/CaM in complex with IQ domains of CaV1-2 channels  ADDIN EN.CITE (; ; ) . Several findings; however, fit poorly with this hypothesis. First, crystal structures of Ca2+/CaM complexed with WT and mutant IQ indicate that the signature isoleucine residue is deeply buried within the C-lobe of CaM and alanine substitutions on this site have negligible perturbations on the overall structure (). Second, Ca2+/CaM  affinities of WT and mutant IQ are very similar (). It is not clear how mutations on the isoleucin residue communicate with different channel domains to produce the observed drastic CDI deficits. Third, in CaV1.2 and CaV1.3 channels the effector site for the N- lobe of CaM is the N-terminal spatial Ca2+ transforming element (NSCaTe) that as the acronym suggests is located on the N-terminus of the channel structure (Fig. 1.2a far right) away from the IQ domain. Fourth, analysis of the crystal structure of CaV2.1 hints that the effector site for the C-lobe of CaM is located somewhere outside the classical IQ domain (). These findings pose serious challenge for the IQ centric hypothesis and necessitate new approaches and ideas in identifying the effector sites for CDI.  
  One major issue with prior IQ-domain analysis was that the experiments were performed with endogenous CaM present. These studies ascribed most of the IQ mutational effects on the weakening of Ca2+/CaM and IQ binding which was not warranted as the IQ mutations could perturb multiple transition steps of the state model in Fig. 1.2a. In this study we systematically investigate the IQ centric hypothesis by focusing on CaV1.3 channels, a member of L-type calcium channels with robust and separable C- and N-lobe CDI components  ADDIN EN.CITE (; ; ). CaV1.3 channels showcase a robust CDI (Fig. 1.2b) when expressed in HEK 293 cells. Compared with the Ba2+ current (grey trace), the calcium current (black trace) shows rapid decline following a fast upstroke. As Ba2+ ions do not bind to CaM (), normalized difference between the two currents after 300 ms conveniently quantifies the extent of steady-state CDI (CDI parameter shown on the side of Fig. 1.2b). Diamond shaped subsystem (Fig. 1.2c below the current trace) is isolated by overexpressig CaMWT to depopulate state E by mass action. The resulting CDI is indistinguishable from CDI under endogenous CaM levels given the very high apoCaM affinity of WT CaV1.3 channels. The C-lobe CDI component is isolated by overexpressing CaM12, a mutant form of CaM which is incapable of binding to Ca2+ ions on its N-lobe. This perturbation pushes the channels out of the state E while preventing the channels from entering states IN and ICN. The current in this case has signature rapid decay as depicted in the bottom of Fig. 1.2d. To isolate the N-lobe CDI component, CaM34 (a mutant for of CaM that is incapable of binding Ca2+ on its C-lobe) is overexpressed in cells to force the channels by mass action into the state IN. The corresponding N-lobe calcium current showcases slower decline over the duration of the depolarizing pulse (Fig. 1.2e). 
  Armed with these new conceptual insights, we systematically scan (with alanine mutagenesis) the IQ domain of CaV1.3 channels to investigate whether the effector site for C- and N-lobe of CaM is the IQ domain or not. What we discover is that the IQ domain is in fact not the effector site, and that both lobes of CaM depart from the IQ domain. 

1.2	IQ Domain  is not the Effector Site for Ca2+/CaM Mediated CDI 





Figure 1.3 Probing functionally relevant Ca2+/CaM interactions. (a) Unique Langmuir relation (equation 1) that will emerge upon plotting channel CDI (defined Fig. 1.2b, right) as a function of Ka,EFF (association constant measured for isolated channel peptide), if Ka,EFF is proportional to one of the actual association constants in the scheme as in Fig. 1.2a. Black symbols, hypothetical results for various channel/peptide mutations; green symbol, hypothetical WT. (b) Predicted outcome if peptide association constant Ka,EFF has no bearing on association constants within holochannels. (c) Outcome if mutations affect holochannel association constants, but not peptide association constants. (d) Outcome if mutations affect holochannel association constant(s) and peptide association constant, but in ways that are poorly correlated.

One possibility is that the data points (each point represents average CDI value of a hypothetical IQ mutation introduced in CaV1.3 and expressed in HEK 293 cells) lie horizontal to the WT point (Fig 1.3 a-d green circle). This implies that the mutations disrupt the peptide binding but leave CDI unchanged because the mutations do not influence any of the CDI transitions pathways within the holochannel. The second case involves vertical positioning of the points relative to the WT point (Fig 1.3c) implying that the mutations do not perturb binding of Ca2+/CaM with the IQ peptide, but do reduce CDI as they perturb the transitions within the holochannel. It is also possible that mutations disrupt transitions governing CDI within holochannel, but in ways that are uncorrelated with perturbation in Ca2+/CaM binding to a corresponding mutant peptide segment (Fig. 1.3d). The red symbol (Fig. 1.3d) denotes a specific subset of point mutations where the specific mutations disrupt the transitions within the holochannel in a manner as to enhance CDI which is uncorrelated with the diminishing of the Ca2+/CaM binding to peptide segment harboring the same mutation.  
 To demonstrate that the IQ domain is indeed the effector site for CDI, the data points must follow a binding (or Langmuir) curve described by the Langmuir equation (Fig. 1.3a, Fig. S1.2):
        (1.1)
 denotes the maximum value of CDI achieved by progressive weakening of the binding.  is the affinity when CDI is 50% of its maximum level. If the plot of CDI versus Ka,EFF for various alanine substitutions follow a Langmuir relation (Eq. 1.1 and Fig. 1.3a), then the domain is the Ca2+/CaM effector site for CDI. Conceptually, the Langmuir correlation implies that weakening the affinities progressively reduces CDI in a way as to follow a binding curve, and lends strong support to the hypothesis that that the IQ domain is the effector site for Ca2+/CaM. This concept may be generalized to identify other Ca2+/CaM effector sites on the holochannel as well. Briefly, if the binding of Ca2+/CaM to domain X of the holochannel is suspected to be the effector site for CDI, alanine mutagenesis coupled with peptide-Ca2+/CaM affinity measurements, can in principle prove whether X is the effector site or not. An observed Langmuir correlation curve (Fig. 1.3a and Fig. S1.2) would mean that X is an effector site, while other configurations (Fig. 1.3b-d) would imply otherwise.
  We systematically mutated each residue on the IQ domain of CaV1.3 to an alanine (to threonine if alanine occurred naturally in that position) and expressed the mutant channels along with CaM12 or CaM34 to isolate C-lobe or N-lobe CDI respectively. We also performed FRET 2-hybrid assays  ADDIN EN.CITE (; ; ) to measure binding between the mutated IQ peptides and Ca2+/CaM in live HEK 293 cells and investigated the correlation between CDI and binding affinities according to the theoretical scheme described in Fig. 1.3.  Fig. 1.4 summarizes the data. The IQ domain sequence is shown on top of Fig. 1.4a. Accordingly, for all the alanine substitutions the N-lobe CDI is the same as or above the WT level (dashed green line).  C-lobe CDI is however drastically attenuated for the signature isoleucine residue (red bar with the exemplar current shown on the right) and the hotspot residues surrounding it (pink bars). For the binding assay, the yellow fluorescent protein (YFP) was fused to specific IQ peptides harboring the mutants. These YFP-fused peptides were then pitted against the cyan fluorescent protein (CFP)–fused CaM. The association constants were then computed as described previously  ADDIN EN.CITE (; ) (Fig. 1.4c far left). Ka,EFF bar graph (Fig. 1.4c) illustrates that none of the alanine mutations on the hot spot surrounding the isoleucine residue disrupts Ca2+/CaM binding to  any appreciable extent. The only mutation that diminishes the binding to Ca+2/CaM is the Y[+3]D mutation (Fig. 1.4c blue circle). Notice that neither C-lobe nor N-lobe CDI is disrupted with Y[+3]D mutation (Fig. 1.4a,b blue circle). The bargraphs already demonstrate the incongruency of the IQ domain as the effector site for C- or N-lobe CDI, but to show this concretely, CDI values are plotted against the association constants in Fig. 1.3d and Fig. 1.3e. For N-lobe CDI, three subsets of points are visible. For one subset of cells, the mutations disrupt the binding and increase CDI (the circles to the left of the green WT circle). For the second subset (the points congregating around the WT circle), mutations do not affect the binding or CDI. For the third subset (the two points to the right of the WT circle), the mutations increase both the binding affinity and CDI. In summary, N-lobe CDI and the affinities do not follow a binding curve. This demonstrates that the IQ domain is not the effector site for the N-lobe of CaM, and that the N-lobe departs from the IQ domain upon its activation by calcium. In fact, the effector site for the N-lobe of CaM has already been determined to be the NSCaTe domain located on the N-terminus of CaV1.3 channels. C-lobe CDI is also uncorrelated with the binding affinities as illustrated by Fig. 1.4e. The structurally severe perturbation Y[+3]D, attenuates binding as described previously, but leaves CDI unchanged (blue point). For four mutations to the left of the WT circle, the binding is diminished while the CDI is left unscathed.

Figure 1.4 Inconsistencies with IQ domain role as Ca2+/CaM effector site. (a) No appreciable deficit in isolated N-lobe CDI upon point alanine substitutions across the IQ domain (sequence at top with bolded isoleucine at ‘0’ position). Left,corresponding subsystem schematic. Middle, bar-graph summary of CDI metric, as defined in Fig.1.2b. Bars, mean±s.e.m. for ~6 cells each. Green dashed line, WT profile; red bar, I[0]A; blue symbol in all panels, Y[3]D. Right, exemplar currents, demonstrating no change in N-lobe CDI upon I[0]A substitution. Horizontal scale bar, 100 ms; vertical scale bar, 0.2 nA Ca2+ current. Red, Ca2+ current; gray, Ba2+ current. (b) Isolated C-lobe CDI (corresponding subsystem schematized on left) exhibits significant attenuation by mutations surrounding the central isoleucine (coloured bars). Format as in a. I[0]A shows the strongest attenuation (red bar and exemplar currents at right). Bars average ~5 cells±s.e.m. Dashed green line, WT profile. Timebase as in b; vertical scale bar, 0.2 nA Ca2+ current. (c) Bar-graph summary of association constants (Ka,EFF=1/Kd,EFF) for Ca2+/CaM binding to IQ, evaluated for constructs exhibiting significant effects in b (coloured bars, with I[0]A in red), or chosen at random (hashed in b). Error bars, non-linear s.d. estimates. FRET partners schematized on the left, and exemplar binding curves on the right for I[0]A (red) and WT (black). Symbols average ~7 cells. Smooth curve fits, 1:1 binding model. Calibration to efficiency EA=0.1, far right vertical scale bar. Horizontal scale bar corresponds to 100 nM. (d) Plots of N-lobe CDI versus Ka,EFF deviate from equation 1, much as in Fig. 1.3b. Green, WT; red, I[0]A; blue, Y[3]D. (e) Plots of C-lobe CDI versus Ka,EFF also diverge from Langmuir, as in Fig. 1.3d. This result further argues against the IQ per se acting as an effector site for the C-lobe of Ca2+/CaM. Symbols as in d. (d,e) Y[3]D (blue symbol, CDI mean of four cells) yields poor Ca2+/CaM binding, but unchanged CDI. Fig.S1.7  and S1.8 for  further FRET data. 
 
For four cells including the signature isoleucin (red circle) the affinities are unchanged while the CDI is attenuated. For the two mutations to the right of the WT circle, the binding is increased while CDI is reduced. In short, C-lobe CDI is Langmuir uncorrelated to the binding affinities, implying that the IQ domain is not the effector site for the C-lobe of CaM, and that C-lobe of CaM may depart from the IQ domain and bind elsewhere on the holochannel. The effector site for C-lobe of CaM is determined with similar Langmuir type analysis to be the PCI region (Fig. 1.2a far right) ().  





1.3 CaM Tuning of RNA- edited CaV1.3 Channels














Figure 1.5 Functional Effects of RNA Editing of CaV1.3 Channels, Hypothesized to Occur as Perturbation of Ca2+/CaM Complexed Alone with Channel IQ Domain (a) Schematic of main pore-forming α1D subunit of CaV1.3 channel. Shown are cytoplasmic amino (N) and carboxy (C) termini, containing main elements implicated in CDI. CI, Ca2+-inactivation region spanning proximal channel carboxy tail (~160 aa). CI contains elements involved in CaM regulation. IQ domain (IQ), terminal CI segment (~30 aa) believed preeminent in binding CaM. Dual vestigial EF-hand region (EF) spanning proximal ~100 aa of CI. NSCaTE element on channel N terminus of CaV1.2 and CaV1.3 channels, proposed as N lobe Ca2+/CaM effector site  ADDIN EN.CITE (; ) (b) Popular hypothesis about how CDI arises from CaM interactions with elements described in (a). In this view, Ca2+/CaM binding to the IQ element alone (right) triggers CDI. ApoCaM may prebind to the IQ element in a different way (left), positioning CaM as a “resident” Ca2+ sensor (c) Homology model of Ca2+/CaM complexed with CaV1.3 IQ domain (dark blue helix, carboxy-terminal end to right). Ca2+ ions, yellow balls (d) Exemplar recombinant CaV1.3 whole-cell currents expressed in HEK293 cells. Leftmost subpanel pertains to prototypic channels with IQDY version of IQ domain. Scale bar (0.2 nA) pertains to Ca2+ current (red) throughout. Black Ba2+ current scaled down approximately three times to facilitate comparison of decay kinetics, here and throughout. CDI metric, defined at right. Other subpanels pertain to various RNA edited variants, demonstrating a spectrum of reduced CDI strengths. Parentheses contain percentage of corresponding transcripts across mouse brain. (e) FRET two-hybrid assay for interaction of CaV1.3 IQ domain and Ca2+/CaM. Left: cartoon of relevant FRET pair. Right: 33-FRET binding curve plots FRET efficiency (EA, from YFP standpoint) versus free concentration of CFP-CaMWT (Dfree). Each symbol, mean ± SEM of n=19 cells. Smooth curve, EA = EA,max Dfree / (KD,EFF + Dfree), where EA,max equals plateau value and KD,EFF is given by x intercept of vertical dotted line. Green bar calibrates Dfree units to nM. See also FigS1.1 (f) Proposed strategy for quantitative confirmation of RNA editing mechanism involving Ca2+/CaM complex with IQ element, as portrayed in (c). CDI metric of particular construct is to be plotted versus corresponding effective association constant Ka,EFF, deduced from data as in (e). Symbols and fit portray hypothetical outcome: green symbol, prototypic IQ species; black symbols, RNA edited variants; smooth fit, Langmuir function as described in main text. See also FigS1.2.

This unexpected outcome suggests that RNA editing changes the affinity of the channels for apoCaM, and that the ambient CaM fluctuations can change the fraction of channels endowed with apoCaM.  In this manner, the strength of CDI can be continuously tuned by cellular CaM levels, an effect we substantiate in substantia nigra neurons. This adjustability of CDI by CaM emerges as a key element of Ca2+ homeostasis throughout the brain.

1.4 Functional Effect of RNA Editing in the IQ Domain of CaV1.3 Channels


 Fig. 1.5d (far left) shows the current trace for the WT IQ domain (IQDY). Such channels comprise ~60% of the transcript in the brain  ADDIN EN.CITE ().  With the WT baseline in mind, we can see the resulting CDI for the RNA edited variants shown to the right of the WT trace. The composition of the central IQ domain is shown on top of each trace along with the prelevance of the transcript  ADDIN EN.CITE (). The reduction in CDI is particularly extreme for MQDY and MQDC variants while MRDY and IRDY variants present intermediate levels of CDI attenuation. As with the alanine mutations described in the previous section, we began by investigating whether the CDI deficits correlate with Ca2+/CaM binding. To measure the binding we tagged peptides harboring RNA editing alterations with YFP and pitted them against CFP tagged CaM. We then measured FRET efficiency () in each cell and plotted the values against CFP to obtain binding curves similar to that shown in Fig. 1.5e. The specific curve here corresponds to the signature WT IQDY peptide indicating Kd~55 nM. If the IQ domain is the effector site, the CDI versus affinity would produce a Langmuir  binding curve (Eq. 1.1)  as illustrated in Fig. 1.5f.  For the typical IQDY module the association constant Ka,EFF (=1/Kd,EFF=1/1700) would be  reciprocal Dfree units, equivalent to an absolute association constant K​a (=1/Kd=1/55 nM) approximating 0.018 nM-1. For completeness of analysis, we proceed by plotting the CDI levels, not only of RNA editing variant, but also the whole IQ domain under endogenous CaM conditions. Fig. 1.6a summarizes the population effects of CDI in both naturally occurring RNA edited variants (blue bars left) and alanine substitutions (grey and rose bars to the right). The dashed green line denotes CDI level for the WT (IQDY) channel and the IQ domain sequence is aligned atop for ease of visualization. Substitutions at several locations result in strong suppression of CDI (rose bars) with the largest effect occurring with I[0] residue. Exemplar currents for I[0]A, A[-4]T, F[4]A, and V[-9]A are shown. We next obtained binding curves for the substitutions that had the largest CDI deficits (Fig. 1.6c). The green line represents the binding curve for IQDY. Except for the slight decrease in V[-9]A, none of the mutations appretiably perturbed binding, and the curves overlapped with that of the IQDY peptide (Fig. 1.6c). We repeated the binding experiments for the RNA editing variants as well and observed no decrease in the binding to Ca2+/CaM (Fig. 1.6d). Consistent with the previously discussed data in section 1.1, these results support the idea that CDI deficits are not because of perturbations in Ca2+/CaM binding to the RNA edited IQ domain. 

Figure 1.6 Ca2+/CaM Effector Role of IQ Domain to Explain Functional Effects of RNA Editing a. Population data for CDI metric of different RNA editing variants (left cluster in blue) and of various point-alanine substitutions (right cluster, rose and gray). Metric for prototypic IQDY species shown in green. Rose bars, strongest CDI reduction by mutations. Dashed gray bars, mutations without appreciable CDI effects that were nonetheless chosen at random for subsequent Ca2+/CaM binding analysis. Bars show mean ± SEM, derived from four to six cells each for editing, and approximately six cells each for the alanine scan. b. Exemplar current traces corresponding to indicated point-alanine substitutions. Format as Fig. 1.5.  in Fig.1.1d. c. FRET two-hybrid interaction curves for Ca2+/CaM versus IQ domain of point-alanine substitutions. As reference, green curve reproduces fit for prototypic IQDY species (from Fig.1.1e). Black data and fits correspond to whole-cell currents directly above in (b). Each symbol bins data from approximately three, four, seven, and eight cells (left to right). d. FRET two-hybrid interaction curves for Ca2+/CaM versus IQ domain of RNA editing variants. Format as in (C). Each symbol bins data from approximately seven, six, nine, and six cells (left to right). e. CDI plotted as a function of Ka,EFF deviates from Langmuir function (Fig.1.1f), arguing against CDI reduction arising from diminished Ca2+/CaM with solitary IQ element acting as effector site. Horizontal bars, SD of Ka,EFF deduced from Jacobian error analysis (). See also FigS1.3.

To rigorously demonstrate this, we plotted CDI levels versus the association constants and observed no Langmuir correlation (Fig. 1.6e). The blue circles correspond to the RNA edited variants. The plot shows that RNA editing disrupts CDI, but does not perturb the binding to Ca2+/CaM.  Indeed, IQ domain does not constitute an effector site for CDI deficits in RNA edited channel variants.

1.5 RNA Editin Perturbs apoCaM Binding to the IQ Domain


















Figure 1.7 ApoCaM Prebinding Role of IQ Domain Explains Effects of RNA Editing (a) Channels require preassociation with apoCaM (configuration A) to undergo CDI. Channels without apoCaM (configuration E) cannot undergo CDI. RNA editing and alanine scanning might perturb association constant Ka for apoCaM preassociation, thereby reducing CDI by populating configuration E. (b) Population data for CDI metric under strong overexpression ofCaMWT (CDICaMhi). Different RNA editing variants (left cluster in blue). Various point-alanine substitutions (right cluster, rose and gray). Metric for prototypic IQDY species shown in green. Rose bars, strongest CDI reduction by mutations in  Fig.1.6a. Gray bars, mutations without appreciable CDI effects in  Fig.1.6a that were nonetheless chosen for CaM overexpression studies. Dashed gray bars, subset of gray-bar constructs chosen at random for additional FRET analysis of apoCaM binding below. Bars show mean ± SEM derived from approximately  five cells each. (c) Exemplar current traces for selected constructs during CaM overexpression. Leftmost subpanel, prototypic IQDY species. Other subpanels, RNA-editing variants and point-alanine-substitution constructs, as labeled. Format as in  Fig.1.5d. (d) FRET assays of apoCaM binding to entire CaV1.3 CI region (cartoon at left). FRET two-hybrid interaction curves. Green data and fit within MQDY subpanel display properties for IQDY construct (symbols bin approximately ten cells each). Black data, interaction data, and fit corresponding to RNA editing variants and alanine-substituted constructs, as labeled. Symbols average approximately four, four, six, and five cells each (left to right). (e) Plotting the ratio of CDI / CDICaMhi (from Fig.1.6a and 1.7b)as function of Ka,EFF decorates Langmuir curve (black line), arguing for apoCaM preassociation function of the IQ domain. Wild-type data in green. See also FigS.1.4 and S1.5. (f) Homology model of C lobe of apoCaM (cyan) complexed with CaV1.3 IQ domain (blue). Left: complex with prototypic IQ domain showing hotspots in red. Right: model with MQDY variant, showing potential steric clash of M[0] with apoCaM.
Remarkably, this simple maneuver restores CDI to the WT level (dashed green line) for all the mutant channels except for the isoleucine where the restoration  is 50% of the WT. The exemplar currents illustrate this remarkable CDI rescue in Fig. 1.7c. To show that the binding of apoCaM is affected for altered IQ domains, we fuse the whole C-tail inactivating region (CI) of the channel (harboring the RNA editing or alanine substitutions) with YFP and pit it against CFP-fused CaM. As shown in Fig. 1.7d, RNA editing substitutions disrupt the binding to apoCaM relative to the WT. Plotting  (in accordance with Eq. 1.1 and Fig. S1.4) versus the association constants obtained by FRET, yields a Langmuir curve demonstrating that the perturbation in apoCaM preassociation is the main culprit for CDI deficits. Remarkably, the alanine substitutions also fall on this curve demonstrating a unified mechanism for CDI deficits in artificial and naturally occurring substitutions. To lend structural support to this idea, homology models of CaV1.3 IQ domain in complex with the C-lobe of apoCaM were constructed based on the analogous NMR structures for NaV channels  ADDIN EN.CITE (; ). Reassuringly, according to the constructed homology structures shown in Fig. 1.7f, alanine substitutions and RNA editied variants would perturb anchor sidechains deeply embedded within the hydrophobic groove of the C-lobe of apoCaM (Fig. 1.7f structure in the left). The green colored methionine residue in the MQDY RNA editing variant peptide-apoCaM complex (Fig. 1.7f structure in the right) clearly demonstrates the steric clash of the methionine sidechain with the apoCaM C-lobe. 

1.6 Continuously Tunable Ca2+ Regulation in Substantia Nigra Neurons

The newly-found understanding of CDI regulation by RNA editing (Fig. 1.7a) opens the possibilitiy for considerable tunability of Ca2+ regulation of CaV1.3 channels beyond initial expectations. The original concept that editing modulated Ca2+/CaM interaction with an IQ effector site would limit the range of CDI adjustments to discrete (and even all or none) range much like the discrete settings on a rotary switch. By contrast, the alternate mechanism involving apoCaM preassociation (Fig. 1.7a) predicts a more flexible mechanism as diagramed in Fig. 1.8a. Viewed in this way, the CDI strength of each variant may smoothly be adjusted by fluctuating levels of naturally ambient CaM (apoCaM) which could variably redistribute the channels between configurations that lack (configuration E) or manifest CDI (configuration A).  In this manner, CDI may be adjusted in the way of a rheostat, with each variant requiring a different level of CaM to achieve half maximal CDI (different values of Ka,EFF). The biological setting where this connection is likely to be of consequence is the dopamine neurons of the substantia nigra par compacta (SNc), whose loss is linked to Ca2+ dysregulation in Parkinson’s disease  ADDIN EN.CITE (; ).  As RNA editing is prominent in these neurons  ADDIN EN.CITE (), we tested for the CaM-mediated upregulaion of CDI in isolated murine substantia nigral neurons as exemplified in Fig. 1.8b by GFP expression under the control of a tyrosine hydroxylase promoter. Under control conditions, CDI level was -
 
Figure 1.8 Tuning of CDI by CaM in Substantia Nigral Neurons. (a) Refocusing the mechanistic scheme to emphasize how changes in ambient apoCaM levels (ΔapoCaM) may continuously tune the strength of CDI. (b) Confocal image of SNc neuron expressing GFP under tyrosine hydroxylase promoter. (c) Whole-cell currents from SNc neurons, averaged from n = 7 (left) and n = 6 (right) cells. Format as in  Fig.1.6d. Left: with endogenous levels of CaM. Right: after strongly increasing CaM levels via pipet dialysis of recombinant CaMWT. See also  Fig.S1.6 (d) Bar graph summary of data at left. (e) CDI-CaM response curves for various RNA editing species, deduced from FRET two-hybrid data in  Fig.1.7d. Black curves, RNA editing species in splice variants lacking a competitive inhibitor ICDI module. Blue curves, parallel behavior of RNA editing species in splice variants containing an ICDI module. (f) Aggregate CDI-CaM response curve (black), averaged over the curves of the entire population of RNA-edited species. Weighting factors specified by transcript and splice prevalence in substantia nigra. Gray and blue zones and curves reproduce response characteristics of individual RNA editing variants. Dashed lines, CDI response and CaM estimates for SNc neurons before and after CaM supplementation, taken from (d). (g) Conceptual scheme of Ca2+ homeostasis, incorporating continuous CaM tuning of CDI strength as projected in (f). Gray outline, generic pacemaking neuron with depolarizing CaV1.3 and hyperpolarizing SK channels. Ca2+-negative feedback gain on CaV1.3 opening is continuously adjustable by CaM (as in f), in the manner of a rheostat-controlled gain element.
 
modest as illustrated by the current trace (Fig. 1.8c left with endogenous CaM, [CaM]endo) averaged for many neurons. Using a FRET-based genetically encoded sensor of CaM (BsCaMIQ), we estimated the free concentration of CaMendo to be 3.91 M (n=7) based on the measurements done on the intrinsically nonfluorescent hippocampal neurons  ADDIN EN.CITE (; ). Dihydropyridine antagonists verified that up to two thirds of the current was carried out by CaV1.3 channels in SNc neurons (Fig. S1.6). Moreover, the CDI strength was half of the value for prototypical IQDY CaV1.3 channels (Fig. 1.8d) measured in HEK 293 cells consistent with significant reduction as a result of RNA editing. Upon perfusion with purified CaM protein (final concentration of ~100M), CDI increased by 2-folds approaching the value of the typical IQDY channel (Fig. 1.8d). This outcome is directly consistent with the tunability of CDI by CaM in SNc neurons.

1.7 Discussion 




Our baseline CaV1.3 construct (α1DΔ1626; or CaV1.3short in  Fig.1.5d) was closely similar to a naturally occurring rat brain variant (α1D, AF3070009  ADDIN EN.CITE (), encoding 1,643 amino acids) that terminates 18 residues after the IQ domain in the carboxy terminus. To facilitate mutagenesis, α1DΔ1626 was engineered with a silent and unique KpnI restriction site at a position encoding amino acids G1538T1539, ∼50 residues upstream of the IQ domain. Additionally,α1DΔ1626 contains a unique XbaI restriction site followed by a stop codon, both of which reside immediately after the IQ domain ending in V1624G1625. The engineered construct α1DΔ1626, as cloned within mammalian expression vector  pCDNA6 (Invitrogen), thereby permitted rapid substitution of mutated segments of ~260 bp between KpnI and XbaI restriction sites. Actual point mutations were introduced via QuikChange mutagenesis (Agilent Technologies), where the template was a short stretch of α1DΔ1626 (~1,500 bp) encompassing the KpnI to XbaI segment, all as cloned within an ~3.5 kb pCR-Blunt II-TOPO vector (Invitrogen). After complete sequence verification between KpnI and XbaI restriction sites, mutated segments were cloned into α1DΔ1626 via these same sites, yielding full-length channel constructs with point mutations. For FRET two-hybrid constructs, fluorophore-tagged CaM constructs were made as described  ADDIN EN.CITE (). Other FRET constructs were made by replacing CaM in these constructs with appropriate PCR-amplified and mutated IQ segments, via unique NotI and XbaI sites flanking CaM  ADDIN EN.CITE (). Throughout, all segments subject to PCR or QuikChange (Agilent) were verified in their entirety by sequencing.
Transfection into HEK293 Cells
For electrophysiology experiments, HEK293 cells were cultured in 10 cm plates, and channels were transiently transfected by a calcium phosphate protocol (). We applied 8 μg of cDNA encoding the desired channel α1 subunit, along with 8 μg of rat brain β2a (M80545) and 8 μg of rat brain α2δ(NM012919.2) subunits. β2a minimized voltage inactivation, enhancing resolution of CDI. Additional cDNAs were added as required in cotransfections. All of the above cDNA constructs were driven by a cytomegalovirus promoter. To enhance expression, cDNA for simian virus 40 T antigen (1–2 μg) was cotransfected. For FRET two-hybrid experiments, transfections and experiments were performed as described  ADDIN EN.CITE (). Electrophysiology and FRET experiments were performed at room temperature 1–2 days following transfection.
Neuron Culture
SNc neurons were isolated from C57BL/6 mice and FVB/N mice expressing GFP under the tyrosine hydroxylase promoter (TH-GFP) (GENSAT  ADDIN EN.CITE (); Rockefeller University). All protocols were approved by the Animal Care and Use Committee of the Johns Hopkins Medical Institutions. Mouse brains were rapidly removed after decapitation and placed in ice-cold solution containing the following (in mM): NaCl, 59.4; NaHCO3, 25; glucose, 25; sucrose, 75; KCl, 2.5; NaH2PO4, 2.3; CaCl2, 0.9; MgCl2, 14.9. Brains were sectioned into 400 μm coronal slices, and SNc dissected using a 22 gauge needle. SNc pieces were enzymatically digested with 3 mg/ml of proteinase XXIII (Sigma) for 1 hr at 37°C in dissociation solution containing (in mM): NaSO4, 82; K2SO4, 30; HEPES (pH 7.4), 10; glucose, 10; MgCl2, 5; at 305–310 mOsm adjusted with glucose. All solutions were continuously bubbled with 95% O2, 5% CO2. Following digestion, pieces were washed in Tyrode’s solution containing (in mM): NaCl, 150; KCl, 4; CaCl2, 2; glucose, 10; and HEPES (pH 7.4), 10; at 305–310 mOsm adjusted with glucose. Tyrode’s solution was supplemented with 1 mg/ml of bovine serum albumin and trypsin inhibitor (Invitrogen). After wash, SNc pieces were moved to DMEM/F12 GlutaMAX (GIBCO) supplemented with 3% fetal bovine serum, N2 supplement, B27 supplement, NEAA, and glia-derived neurotrophic factor (GDNF) (25 ng/ml). The pieces were triturated into isolated neurons with a series of glass pipettes and plated on glass coverslips coated with poly-L-lysine and incubated at 37°C, 95% O2, and 5% CO2 until experiments performed between 1 and 5 days later. SNc neurons were identified by characteristic size and morphology, as exemplified by GFP expressing neurons from TH-GFP mice.
Whole Cell Recording
For both recombinant channels in HEK cells and endogenous channels in SNc neurons (C57BL/6 mice), whole-cell recordings were obtained at room temperature using Axopatch 200A or 200B amplifiers (Axon Instruments). Electrodes were pulled with borosilicate glass capillaries (World Precision Instruments, MTW 150-F4), resulting in 1–3 MΩ resistances, before series resistance compensation of 80%. The internal solutions contained (in mM) CsMeSO3, 135; CsCl2, 5; MgCl2, 1; MgATP, 4; HEPES (pH 7.3), 5; and BAPTA, 10; at 290 mOsm adjusted with glucose. The bath solution contained (in mM): TEA-MeSO3, 140; HEPES, 10 (pH 7.3); CaCl2 or BaCl2, 40; 300 mOsm, adjusted with glucose.

FRET Optimal Imaging
FRET two-hybrid experiments were carried out in HEK293 cells and analyzed, largely as described  ADDIN EN.CITE (). During imaging, the bath solution was a Tyrode’s buffer containing either 2 mM Ca2+ alone for apoCaM interaction experiments or 2 mM Ca2+ and 10 μM ionomycin to elevate intracellular Ca2+ forCa2+/CaM interaction experiments. In parallel experiments with cells expressing the genetically encoded Ca2+ indicator TN-XL  ADDIN EN.CITE (; ), we confirmed that our ionomycin treatment achieved saturating concentrations of Ca2+ with respect to CaM binding. Concentration-dependent spurious FRET was subtracted from raw data prior to binding-curve analysis  ADDIN EN.CITE (; ). Acceptor-centric measures of FRET were obtained with the33-FRET algorithm as described  ADDIN EN.CITE (). Complementary donor-centric measures of FRET were obtained with the E-FRET method  ADDIN EN.CITE (; ). In vitro binding assays were performed as described previously  ADDIN EN.CITE (). SD error bounds on KD,EFF estimates were determined by Jacobian error matrix analysis (). BSCaMIQ sensor measurements of free CaM concentration at rest were determined by previously established protocols  ADDIN EN.CITE () on mouse hippocampal neurons, cultured () and transiently transfected with plasmids encoding the sensor using polyehtylenimine PEI reagent (Polysciences). Sensor measurements in this setting were favored because of the readily transfectable nature of hippocampal versus SNc neurons.

Homology Modeling of Ca2+/CaM Complexed with CaV1.3 IQ Domain
We used the python-based homology modeling software MODELER () to build models of the CaV1.3 IQ domain (comprising positions −12 through +11 in Fig.1.6a) bound to Ca2+/CaM. Briefly, to model Ca2+/CaM bound IQ domain, we used CaV1.2 structure (2BE6  ADDIN EN.CITE ()) as a template. The IQ domains of CaV1.2 and CaV1.3 are different only by a single residue (E[+2] versus D[+2]). Molecular models and atomic structures were visualized and rendered using PyMOL v.1.2r1 (DeLano Scientific).

Homology Modeling for C Lobe of apoCaM Complexed with IQ Domain






















Figure S1.2 Langmuir Equation Analysis of Ca2+/CaM Effector Site, Related to Fig.1.5f. Explicit formulation of Langmuir equation analysis, assuming selective mutational perturbation of Ca2+/CaM binding to effector site (γ1 step). State 1, preassociated apoCaM bound to channel. State 2, transient apoCaM unbinding in channel alcove. State 3, Ca2+ binding to CaM in alcove. State 4, CDI state, with Ca2+/CaM bound to channel effector site (rectangular insets). For approximate representation of the CDI process, we adopt the four-state configuration above in Fig.S1.2. This configuration is closely similar to those previously published to describe CDI (). Briefly, state 1 represents the channel prebound to apoCaM, at the dual-oval preassociation site cartooned in this complex. Occasionally, apoCaM may flicker off as an unbound apoCaM that is nonetheless ensconced within a channel ‘alcove,’ as illustrated in state 2. Ca​2+ may bind to the four EF-hand loops within CaM, yielding state 3. As the primary source of Ca2+ in our experiments (with a high concentration of the rapid and high-affinity Ca2+ chelator 10 mM BAPTA present in the pipet dialyzate) is Ca2+ fluxing inward through individual channels, Ca2+ driving CDI will mainly be present only when the channels is open (), at a large and fixed Cspike value () approximating some tens of micromolar (). Thus, the on rate constant relating to transitions from states 2 to 3 is approximated by PO . kon .Cspike4, where PO is the open probability of channels in configuration A (main text, Fig.1.7a). From this point, Ca2+ may unbind from CaM to yield state 2, or Ca2+/CaM may bind the effector site to yield state 4. State 4 corresponds to channels that have undergone CDI, and exhibit a diminished open probabilityPO/CDI.Given this or like representations, we can derive the explicit Langmuir form appropriate to mutations that selectively influence the Ca2+/CaM effector step γ1. If FRET 2-hybrid measurements yield Ka,EFF = γ1 / s, where s is a fixed constant of proportionality, then the following specific Langmuir equation arises
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Figure S1.3 Expanded Evidence against the IQ Domain as Effector Site forCa2+/CaM, Related to Fig.1.6e. (a-d) Ca2+/CaM binding and electrophysiological data for various point substitutions within the CaV1.3 IQ domain (labeled at far left). Left column shows 33-FRET binding curves in black, with constructs diagrammed at top. For ease of visual comparison, the green trace reports the wild-type interaction relation (derived from main text Fig.1.5e) scaled to a common maximal Emaxamplitude (scale bar at far right). Single-cell FRET measures binned into symbols averaging ~8, 3, 9, and 8 cells for respective panels a-d. Right column, CDI measured with only endogenous CaM present. Red trace using Ca2+ as charge carrier, with corresponding 0.2 nA scale bar at right. Black trace with Ba2+ as charge carrier, amplitude scaled to facilitate comparison of decay kinetics. Overall, note that T[-10]A (a) did disrupt binding of Ca2+/CaM to the IQ peptide, but alanine substitutions at many other loci did not appreciably alter Ca2+/CaM interaction, as shown in the remaining panels. Interestingly, the decrement in CDI did not seem to correspond with decreased binding, as illustrated in (b) by L[-1]A for which CDI was about halved, while binding remained unchanged


Figure S1.4 Langmuir Equation Analysis of apoCaM Preassociation Site. Langmuir Equation Analysis of apoCaM Preassociation Site, Related to Fig.1.7e Model configuration for understanding exchange of apoCaM with channels. Since, apoCaM preassociation occurs under Ca2+-free conditions, we consider only states 1 and 2 in our 4-state model. Additionally, to account for exchange of apoCaM from cytosol into the alcove of a CaV channel, we introduce a new state 2′ where apoCaM resides outside the channel alcove. Here, the rate constants kin and kout will account for diffusion of apoCaM. Nav, Avogadro’s number. Valcove, effective volume of channel alcove for apoCaM.The evidence for 1:1 apoCaM interaction with the CI region has been presented elsewhere (). For purposes of deducing the Langmuir form of CDI dependence upon channel affinity for apoCaM, a modified version of the scheme in Fig.S1.2 can be considered. Since apoCaM exchanges slowly with the channel ()(≥10 s of secs), the majority of the exchange occurs while intracellular Ca2+ is very low, during 20-30 s rest periods between brief voltage pulses with 10 mM BAPTA in the whole-cell pipet dialyzate. To deduce the fraction of channels with apoCaM preassociated ( = Fb as defined in the main text), therefore, we only need to consider bulk exchange with states 1 and 2 (relevant to Ca2+-free conditions) of the 4-state model. This yields the configuration shown in Fig.S1.4 above, where state 2′ depicts a channel lacking CaM in its alcove; ε is apoCaM affinity for the channel; and Cbulk is the concentration of free apoCaM in bulk cytoplasm. Note that there is no meaning to an interconnection between states 1 and 2′ because a channel can only directly release apoCaM into its alcove (). Based on this configuration, it is straightforward to calculate the equilibrium value for the fraction of channels with onboard CaM, which turns out to equal:
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When ε → 0, channels exhibit negligible CDI as observed experimentally in  ADDIN EN.CITE (). Hence, it must be that
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With this knowledge, we obtain the simplified Langmuir form
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In the main text, we can experimentally gauge Fb for a given construct by measuring the 




































Figure S1.8 Ca2+/CaM binding  and electrophysiology data for Y[+3]D substitution in the CaV1.3 IQ domain. Forma as in Fig.S1.8. Symbols in panel a  average ~10 cells each
                  
















 Chapter 2 

Genetically Encoded Sensor of Calcineurin Activation
2.1 Background

The phosphatase calcineurin (PP2B), first isolated by affinity chromatography (),  is a central component of  many calcium signaling pathways relaying elevated calcium signals from the plasma membrane to the nucleus. It is the only phosphatase that is directly modulated by a second messenger. Structurally, calcineurin (CN) is comprised of two subunits, a regulatory subunit calcineurin-A (CalNA, ~60kD) and a CaM-like calcium binding subunit calcineurin-B (CalNB, ~19kD). CalNA has three isoforms encoded by PPP3CA (), PPP3CB (, and PPP3CC ( genes. CalNA contains the catalytic phosphatase domain, Ca2+/CaM binding domain, and the autoregulatory domain that under basal calcium levels binds to and blocks the catalytic domain, and prevents the activation of the phosphatase (Fig. 2.1a). The CalNB domain which has two isoforms encoded by PPP3R1 and PPP3R2 is a CaM-like molecule that has four EF-hand domains capable of binding four calcium ions. The two calcium binding sites on the N-terminus have high affinity for these  ions and are occupied under basal low calcium conditions (50 nM - 100 nM), while the two sites on the C-terminal domain bind calcium with low affinity (Kd~0.5 µM), and are occupied by calcium ions  when the intracellular calcium concentrations rise to hundreds of nM  ADDIN EN.CITE (; ; ; ; ). The low-affinity calcium binding sites on the CalNB subunit contribute to ~10% of the overall activity and stabilize the structure of activated calcineurin  ADDIN EN.CITE (; ; ). Fig. 2.1 (reproduced with  permission of the publisher from () ) illustrates the domain structure of the two subunits along with the  proposed kinetic pathways contributing to CN activation. The most well known target of CN is the Nuclear Factor of Activating T cells (NFAT). NFAT was first discovered as a downstream signaling molecule activated following the engagement of T cell receptor (TCR) with an antigen  ADDIN EN.CITE (; ). It was subsequently discovered that the immunosuppressent compound cyclosporin-A (CsA) specifically blocks the nuclear localization and DNA binding effects of NFAT  ADDIN EN.CITE (). Shortly thereafter, another landmark paper discovered that the NFAT inhibitory effects of cyclophilin-cyclosporinA and FKBP-FK506 complexes are attributable to the direct and potent inhibition of CN phosphatase activity by these compounds  ADDIN EN.CITE (). The identification of CN as the target of the immunophilin-immunosuppressents suggested that CN is involved in the common step associated with T cell activation. Subsequent investigations overexpressed CN in Jurkat T cells and demonstrated that this action rendered the cells more resistant to the action of CsA and FK506, and augmented NFAT activation  ADDIN EN.CITE (). Moreover, cytoplasmic NFAT was found to be a substrate for CN  ADDIN EN.CITE (). 
 Although the immune system has been the classical context for discoveries regarding the CN-NFAT pathway, it was soon realized that this pathway is also critical for the development and function of a wide range of cell types and tissues. For example, axonal growth was critically dependent on CN-NFAT. Mice defective in CN signaling show severe defects in axonal growth, and responde poorly to neuronal growth factors such as netrin-1 and neurotrophins. Interestingly, the mice showed no defect in neuronal differentiation and survival  ADDIN EN.CITE (). CN is also activated by neuronal firing in hippocampal neurons suggesting a role in learning and memory. It has been observed that NFAT is imported to the nucleus in hippocampal interneurons following L-type calcium channel activation  ADDIN EN.CITE (). CN has also been found to be an important regulator of  the speed of rapid and slow synaptic cycling in central synapses in mice and rats  ADDIN EN.CITE (, ), and is also implicated in synaptic plasticity by limiting the synaptic incorporation of AMPA receptors  ADDIN EN.CITE (). The bath application or postsynaptic injection of CN inhibitors is shown to prevent NMDA dependent synaptic long term depression​[2]​  ADDIN EN.CITE (; ; ; ; ). Further, LTD was blocked by CN inhibitors in hippocampal slices from adult, but not two-week old  rats suggesting a developmentally regulated role for CN in LTD induction  ADDIN EN.CITE ().  It was further shown that induction of LTD in rat hippocampal slices required CN in complex with the scaffolding protein AKAP79/150  ADDIN EN.CITE (). 
  Shifting attention to  other tissues, CN signaling is also critical for normal cardiac valve and septum development and morphology  ADDIN EN.CITE (; ), cardiac myocyte differentiation  ADDIN EN.CITE (), pancreatic beta cell growth and function (), Schwann cell differentiation  ADDIN EN.CITE (), and normal vascular development  ADDIN EN.CITE (). Disruption of CalNB1 subunit in the heart results in abnormal cardiac growth, disrupted systolic and diastolic function, lower bi-ventricular to body weight ratio, and 100% mortality by the age of 7 months  ADDIN EN.CITE (; ). CN-NFAT pathway is also critically linked to cardiac metabolic pathways  ADDIN EN.CITE (). 

Figure 2.1 Domain Structure of Human Calcineurin (). (a) Calcineurin-A subunit (1- 521 aa) consists of the catalytic domain that caries out the phosphatase function (71-342 aa), the Calcineurin- B subunit binding site (348-370 aa), CaM binding region (391-414 aa), and the autoinhibitory peptide ( 457-482 aa)  that binds and blocks the activation of the catalytic domain. Human Calcineurin- B subunit (1- 170 aa) has 4 EF-hand domains each binding to a calcium ion. The EF1 and EF2 are high affinity binding sites occupied under basal conditions, while the EF3 and EF4 are low affinity. (b) Sequence of kinetic events involved in CN activation. Under basal conditions, the autoinhibitory peptide blocks the catalytic domain of CaLNA (I). Calcium binding to CalNB partially activates Calcineurin (~10%), and stabilizes the structure of the complex (II). Ca2+/CaM binding to CalNA displaces the autoinhibitory peptide (III) resulting in fully active Calcineurin conformation (IV).

Aside from its function in normal biological processes, there also exists a vast and accumulating body of literature for the role of CN/NFAT in pathophysiological states. To further motivate the results of this chapter, we consider the role of CN/NFAT signaling in relation to three important human diseases: Alzheimer’s disease, cancer metastases, and cardiac hypertrophy. 
  Alzheimer’s disease (AD) is a neurodegenerative disease characterized by the loss of neurons, the accumulation of extracellular plaques, and intracellular neurofibrilliary structures. Recent genetic studies have identified single nucleotide polymorphisms (SNPs) associated with the rate of disease progression. One of these SNPs is located on the regulatory domain of CN  ADDIN EN.CITE (, ). Optical methods based on fluorescence resonance energy transfer (FRET) have shown that shortly after the treatment of wild type cells with Amyloid beta, derived from a mouse model of AD or human AD brains, CN gets activated within minutes and leads to rapid   morphological changes and subsequent loss of synaptic spines. NFAT is also translocated to the nucleus following longer exposures  ADDIN EN.CITE (, ). In other studies, constitutively active NFAT mimicked neurotoxicity associated with amyloid beta, and inhibition of the NFAT pathway by a short peptide (containing the VIVIT  amino acid sequence) alleviated spine loss and morphology changes  ADDIN EN.CITE (; ). In assays of  NFAT cytoplasmic and nuclear localization determined in samples from rapidly autopsied postmortem human tissues, the NFAT nuclear localization pattern is differentially modulated depending on different levels of cognitive function and disease progression  ADDIN EN.CITE (). Overall, a growing body of evidence suggests a crucial function of the CN/NFAT pathway in regulating different aspects of AD that might provide potential avenues for future therapeutic intervention. 
  Turning now to cancer metastasis, there is an emerging consensus for the role of CN/NFAT signaling in cancer biology and tumor angiogenesis (). NFAT1 and NFAT5 are expressed in invasive breast ductal carcinomas and promote carcinoma invasion (). Sustained CN activation is observed in B- and T-cell lymphomas and in mouse models of lymphoid diseases. Inhibition of CN activity by CsA or FK506 leads to apoptosis of leukemic cells and tumor clearance, and prolongs mouse survival. Moreover, the expression of a constitutively active mutant of CN favors leukemia progression  ADDIN EN.CITE (). Application of CsA attenuates endothelial proliferation and pathological angiogenesis in cancer  ADDIN EN.CITE (). Further, targeted deletion of the CN inhibitor gene DSCR1 suppresses angiogenesis and tumor growth  ADDIN EN.CITE ().  Indeed, the study of 2814 patients with Down’s syndrome has shown that these patients have a strikingly lower incidence of cancer than the general population (), which  may partly be attributable to the extra copy of DSCR1 gene  ADDIN EN.CITE (). Paradoxically, there is significant increase in cancer incidence in patients on long term immunosuppressent treatment (). This neoplastic propensity is probably due to decreased anti-tumor immune function and also re-activation of the quiescent Epstein-Barr virus (EBV)-transformed B lymphoctes. Blocking CN can also prevent dephosphorylation and activation of the targets that negatively affect tumor growth and survival. More selective (more selective than CsA and FK506) peptide inhibitors of NFAT termed VIVIT (as they contain the consensus sequence VIVIT), potently block NFAT dephosphorylation and nuclear translocation  ADDIN EN.CITE (; ; ), prolong survival in fully mismatched islet allografts in mice  ADDIN EN.CITE (), and inhibit breast cancer invasion (). Overall, there is an emerging consensus favoring a significant role for CN/NFAT signaling in cancer modulation that might provide a potential target for anti-cancer therapy.
  Given that CN is the only phosphatase that is directly activated by a second messenger, it is no surprise that CN plays a prominent role in cardiac pathology. In the heart, CN/NFAT pathway has been found to be a central regulator of pathological hypertrophy (characterized by increased myocardial size and the activation of fetal genes) both in vitro and in vivo  ADDIN EN.CITE (). NFAT-luciferase activity is dramatically increased following pressure overload or myocardial infarction induced heart failure, but not by exercise induced cardiac enlargement  ADDIN EN.CITE (; ; ). Presence of a constitutively active CN transgene  ADDIN EN.CITE () in adult mice, results in the activation of the fetal genes, fibrosis, and cardiac growth, all reminiscent of pathological hypertrophy  ADDIN EN.CITE (; ). This is also consistent with the finding that cardiac CaM overexpression in mice leads to massive hypertrophy (). Recent studies using left ventricle samples from  human heart failure patients have demonstrated about 4-fold increase in CN activity compared to control subjects (). It has further been shown that inhibition of CN by CsA prevents pathological hypertrophy in a mouse model of hypertrophic cardiomyopthy (HCM)  ADDIN EN.CITE (; ).  Considering the failure of traditional therapies for hypertrophy such as angiotensin- converting enzyme (ACE) inhibitors, blockers, and Ca2+ channel inhibitors, more selective modulators of CN/NFAT pathway promise an alternative approach to therapy, and reinforce the need for more aggressive research in elucidating the precise role of  CN/NFAT dynamics in the onset of  cardiac hypertrophy  ADDIN EN.CITE (; ; ; ).  

 2.2 A FRET-based Tool for Dissecting the Spatial and Temporal Dynamics of CN Activation in Live Cells
Traditional biochemical methods have been very powerful in elucidating the basic biology and structure of CN activation in different cell types  ADDIN EN.CITE (; ; ; ; ; ; ). However, these population-based tools require fixing of cells and are not suitable for assaying CN dynamics in single live cells. Recent progress in the development of fluorescent-based genetically encoded sensors has opened new windows into studying the complex dynamics of signaling pathways in cells. The advantage of genetically encoded sensors is that they provide a way of targeting the sensors to various organelles and cellular structures in order to study the spatial and temporal variations in protein dynamics. In theory, it should also be straightforward to generate transgenic animals harboring the particular sensor and to investigate protein activation and dynamics in different temporal points and spatial regions of the transgenic animals. These sensors utilize the physical phenomenon of  FRET to assay nano-scale conformational dynamics  in response to activating signals (). The rate of energy transfer by FRET depends sensitively on the distance r (~) between the fluorophores, orientation of the fluorophores relative to each other (the parameter  below ranges between  0-4), and the refractive index of the media (the parameter , ranges from 1/3-1/5 ).  The equation for the rate of energy transfer by FRET is as follows ():

 is the normalized donor emission spectrum. The integration is carried out within the overlap region between the donor emission and acceptor absorption. is the FRET transfer efficiency.  is the unperturbed donor lifetime and is the rate of radiative transfer. The sensitive dependence of FRET on distance and orientation of the fluorophores provides a powerful method to study protein-protein interactions and conformational dynamics of single proteins in single live cells, and with more sensitive probes in live animals. Impressive array of genetically encoded sensors have already been developed to assay the dynamics of Ca2+  ADDIN EN.CITE (; ; ; ), PKA (), PKC  ADDIN EN.CITE (), cGMP (), PI3K/AKT (), cAMP  ADDIN EN.CITE (), CaMKII  ADDIN EN.CITE (; ; ), and calcineurin  ADDIN EN.CITE (; ; ).
  In this chapter we describe the development of a genetically encoded sensor of CN activation showcasing improved dynamic range and kinetics and demonstrate its function and deployment in HEK293 cells, neonatal rat ventricular myocytes (NRVMS), and acutely isolated adult guinea pig ventricular myocyte (AGPVMs). To our knowledge, this is the first genetically encoded sensor of CN capable of responding to sub-second calcium fluctuations in primary cells. We also construct a red fluorescent-based probe for NFATc1 (NFAT2) to co-assay NFAT nuclear translocation dynamics in response to CN activation. Moreover, by combining mathematical modeling with data gathered from the sensor, we formulate a remarable conjecture (consistent with the current understanding of CN in the heart) for tuning of CN activation by CaM in acutely isolated adult cardiac myocytes. 
  Fig. 2.1 ()  outlines a 4-state kinetic model for the activation of CN complex in response to calcium elevation. The first step in this process involves the binding of 2 Ca2+ ions to CalNB that results in partial activation of CN. Full activation ensues following the binding of Ca2+/CaM to the C-terminal CaM binding domain of CalNA, forcing the displacement of the autoinhibitory (AI) domain and large conformational changes relative to the CalNB N-terminus. We hypothesized that this conformational change would be detectable with FRET and proceeded to fuse Cerulean Fluorescent Protein (CFP) to the N terminus of CalNB (CalNB1 isoform) and Venus Fluorescent Protein (VFP) to the C terminus of CalNA subunit (CalNAα isoform)  ADDIN EN.CITE ()​[3]​. Our initial approach was to fuse the two domains using glycine linkers (Glyn) of various lengths; however, it was soon apparent that transfecting the constructs in HEK293 cells resulted in severe  puncta formation and toxicity.  It also seemed that the existence of long glycine linkers introduced instability in the response of the sensors to ionomycin. To alleviate the problem of puncta formation and simultaneously preserve quantitative 1-1 stoichiometry between CalNB1 and CalNAα, viral 2A sequences were employed to fuse the two subunits together as shown below in Fig. 2.2 (; ).


Figure 2.2 The Design of DuoCalN and UniCalN Sensors of CN Activation. (a) Dual CN (thereby called DuoCalN) sensor constructed from fusing CalNB1 to CFP and CalNAα to VFP, and pairing the two together with a p2A-based linker  to ensure quantitative 1-1  stoichiometry. (b) Unimolecular CN sensor (hereafter called UniCalN) is constructed by fusing the two fluorescent domains together with a mutated (and thus ‘uncleavable’) P2A sequence. The working hypothesis is that raising calcium concentration will result in reduction in FRET ratio relative to the baseline.

2A peptide sequences, first identified by Ryan and colleagues (), are short amino acid sequences (~20 aa) derived from different members of the picornavirus family. Placing the sequences between the genes of interest results in equal stoichiometric expression at the protein level. This remarkable technology has been used to generate multi-cistronic expression vectors for various applications including correction of multi-gene deficiency in a mouse model lacking a functional T-cell receptor (TCR):CD3 complex (), and expressing multi-genes to manipulate brain circuits in vivo  ADDIN EN.CITE (). Pertaining to the mechanism of action of the 2A peptide sequences, a ribosome skipping mechanism is proposed to explain the  ‘self- processing’ of the gene products and as a result of this idea, the 2A sequences are now  referred to as CHYSELs (cis-acting hydrolase elements)   ADDIN EN.CITE (; ).  Below is a list of the most commonly used 2A sequences in the literature along with the corresponding viral origin  ADDIN EN.CITE (). Note the conservation of the C-terminal NPGP sequence and also the presence of a flanking N- terminal GSG sequence for proper hydrolase activity. Addition of the three amino acid N-terminal sequences was found to be absolutely necessary for proper hydrolase and self- processing function in vivo (). 
We selected the corresponding 2A sequence derived from  porcine tescho virus (P2A) with variable flanking N-terminal sequence additions and tested the self-processing efficacy of these sequences  in vivo with 33- FRET  ADDIN EN.CITE (; ). We conjectured that adding N-terminal flanking sequences derived from the actual viral sequence may improve the efficiency of the P2A sequence and provide a more rational basis for the P2A design. The Following amino acid sequence depicts the portion of the porcine tescho virus containing the P2A sequence (the N-terminal flanking sequences underlined and the P2A sequence highlighted in yellow):
LSATDPIEKAKDSVDNYALPSFTWKPAQTPVFTCSVPYVSFNSVLPAMYSGFETSSKIPKRNNQIPQDFGFGMLVLRSSSTAGLAVSVWVKFENVRLFCPRPGIHDPLAYSRSHPQESREHDEGLSSAMTVMAFQGPGATNFSLLKQAGDVEENPGPSLSKLYQILKDPAVDALCEAYDELKKFKEQATNLLDSFSGDSENPWLNKFIKYLGYAILAWKSLHDPMTAAAVCFIIGSDVTAFVVSKLAKHLKKFAKTDSPPVPKPRSCKKEGCCCGNKHNYPDELNPFSENGFWSRFKKGH
The bar graph in Fig. 2.3a shows the ratio of donor (CFP) to acceptor (VFP) molecules computed from 33-FRET measurements  ADDIN EN.CITE (; ).   The ratio is close to 1 for the P2A constructs. Fig. 2.3b, illustrates the FRET ratio (FR) plotted against the Cerulean (CFP) fluorescence levels. FR values of close to 1 indicate that the fluorescent proteins are completely separated (‘cleaved’ or self- processed). 

Figure 2.3 Analysing the Efficiency of the P2A Peptides with 33- FRET Technology. (a) The ratio of the donor (CFP) to acceptor (VFP) molecules computed by 33-FRET.  Variations of the P2A sequences along with the flanking N-terminal addition sequences sandwiched between Cerulean (CFP) and Venus (VFP). P2A (C-P2A-V with no N-terminal flanking sequences), GSGP2A (C-GSG-P2A-V), GPGP2A (C-GPG-P2A-V), QGPGP2A (C-QGPG-P2A-V), FQGPGP2A (C-FQGPG-P2A-V), MAFQGPGP2A (C-MAFQGPG-P2A-V) all result in 1-1 stoichiometry (b) FR vs. SCER plot showing the FRET ratio vs. Cerulean fluorescence. All N- terminal flanking additions result in FR values of close to 1. P2A without the added N- terminal sequences (C-P2A-V) and the mutant P2A (NPGPAAAA) have high FR (~5-6) indicating no fluorophore separation. 

As expected from the literature, the addition of N-terminal sequences (GSG, GPG, QGPG, FQGPG, and MAFQGPG shown in Fig. 2.3) is essential for proper P2A hydrolysis function  ADDIN EN.CITE (; ). In the absence of any flanking sequences, the construct C-P2A-V acts as a dimer with high basal FR (Fig. 2.3b). Furthermore, mutating the consensus C-terminal NPGP sequence (to AAAA) abolishes the self-processing function of P2A. Two types of sensors are constructed by fusing CFP-CalNB1 and CalNAα-VFP. The DuoCalN sensor (Dual CN) is based on using the FQGPGP2A sequence between the fluorescent domains. The UniCalN sensor (Unimolecular CN) is constructed by using the mutant form of P2A (GSGP2Amutant) where the conserved NGPGP sequence was substituted by AAAA (Fig. 2.3b). The plasmid maps (above) and domain structures (below) are shown in Figs. 2.4a and 2.4b. The sensors are then transfected in HEK293 cells to gauge and calibrate the FRET response of the sensors to acute elevations of intracellular calcium concentrations.








2.3	Calibrating the Calcium Response of the Sensors

HEK 293 cells are transfected with the DuoCalN and UniCalN sensors and loaded with the ratio metric calcium dye Indo-1​[4]​ (). The absorption spectrum of Indo-1 lies in the UV region and thus offers the possibility of co- imaging with CFP, VFP, and FRET.  


Figure 2.5 The FRET Response of DuoCalN and UniCalN to Calcium Transients Induced by the Addition of Thapsigargin. (a) Left column, thapsigargin elicits a calcium transient of 500 nM amplitude and duration of ~500 s. (b) Sensor responds by 50% change in FRET efficiency. (c) FRET signal decreases. (d) CFP signal increases consistent with the expected conformational changes in CN complex.  Right column, for a cell transfected with UniCalN sensor. (e) Calcium amplitude is about 300 nM with the duration of ~600 s. (f) The corresponding FRET efficiency change is ~ 25%. (g) FRET signal has a downward transient as expected. (h) CFP signal shows the expected upward transient.  is the normalized FRET efficiency, whereindicates the basal value of FR.

Slow calcium transients are elicited by applying thapsigargin​[5]​ to cells placed in Tyrode solution with low extracellular calcium concentrations (0-400 µM). As shown in Fig. 2.5, the calcium transient activates the sensor and leads to a decrease in normalized FR efficiency (E/E0 where E=FR-1). Furthermore, there is a subsequent return to the initial level following the decay of calcium to its basal level. In HEK 293 cells, the transformation from Indo-1 ratio to calcium () is achieved by the following: 
As a result of the thapsigargin induced slow (~10 min total duration) calcium transients, we can safely assume that the system stays at a quasi- equilibrium state. This assumption can be exploited to calibrate FR according to the cellular calcium concentration levels.  FR is normalized according to the form, , and plotted against [Ca] (nM). This is done for each individual cell at each time point. Fig. 2.6a shows the resulting calibration plots for individual representative cells for DuoCalN sensor. Note that the trajectories of some of the cells in FR versus [Ca] space show significant hysteresis and departure from the steady- state (this is nonetheless consistent with the quasi-steady state assumption for the system dynamics under slow calcium transients). 
        




Figure 2.7 Quasi Steady-State Calcium Calibration of UniCalN Sensor. (a) Individual calibration curves for 30 cells each elicited by the application of thapsigargin with cells placed in 0-400 µM Ca. DuoCalN robustly and transiently responds to the thapsigargin induced calcium transients. Single Hill curve with n=3.8 and Kd =300nM fits the data (b) Cumulative calibration plot containing the all the data points for 13 cells. FR is normalized by                                        .


The cumulative calibration plot containing the temporal data points from 30 cells is shown in Fig. 2.6b with the fitted Hill calibration equation also shown on the plot. Fig. 2.7a and Fig. 2.7b present parallel set of results for the UniCalN sensor.  
  According to Fig. 2.1, it would seem that six calcium ions would be necessary for full activation of CN. The binding of two calcium ions partially activates CalNB (~10%) and stabilizes the structure; while, the additional four calcium ions are necessary for activating CaM. According to our calcium calibration data here, a single curve with hill coefficient of n=3.8 fits all the cellular data. This implies that there is high level of cooperativity between the six calcium binding sites. This result is quantitatively consistent with biochemical measurements of the dependence of CN  phosphatase activity on calcium concentration carried out by Klee and colleagues (), who discovered strong cooperativity with a hill coefficient of 3. They () conjectured that at least three calcium ions are necessary for full activation of CN. Moreover, they discovered that in the presence of 300 nM of CaM, the half- maximum activation of CN occurred at calcium concentrations of around 1 M. Our FRET data coupled with simultaneous calcium measurements in the presence of cytoplasmic levels of CaM (~1 µM) suggest that four calcium ions are required, and that half-maximum activation occurs at calcium concentrations of around 300 nM. It is quite satisfying that our FRET-based assay measuring CN conformational activation converges with previous biochemical data measuring actual CN phosphatase activity. This observation hints that the output from our sensors is in fact linearly related to CN activity, as both activity and FRET activation measurements follow a Hill curve when plotted against calcium concentrations. 

2.4	Maximum FRET Response of the Sensors
To determine the maximum calcium response of the sensors, they were transfected in HEK 293 cells with saturating amount of CaM achieved by overexpression.  Our conjecture was that since CaM binding is a prerequisite for sensor activation, CaM overexpression would saturate the sensors and result in maximal activation.  Indeed, after the application of 5 µM ionomycin​[6]​, the steady-state FR value was 1, implying that there was no FRET in the fully active sensor conformation (~1.19 for DuoCalN and ~1 for UniCalN).  Accordingly, the percent FR change (dynamic range) was around 90% for DuoCalN and 100% for UniCalN. We looked at 3 cells transfected with the sensors and CaMWT and the response in each cell was similar to the exemplar plots in Fig. 2.8. 
 The data discussed above demonstrate the utility of the sensors in effectively responding to slow calcium transients (~10 min duration) elicited by thapsigargin. Ionomycin in the presence of elevated CaM levels in HEK 293 cells (Fig. 2.8), resulted in near-complete abolition of steady-state FRET in high calcium conditions in both sensors with 90-100% reduction in FR. Near-perfect dynamic range coupled with rapid kinetic response, promise important applications of these sensors in vivo, where large motion artifacts and background fluorescence levels have challenged the utility of the currently existing FRET-based sensors. 
  It would be instructive to compare the dynamic range of DuoCalN and UniCalN sensors with the currently available FRET sensors of PKA, CaMKII, and calcineurin. The PKA sensor is designed by linking a phosphobinding domain from 14-3-3τ protein with a PKA consensus peptide substrate, and sandwiching the construct between Cyan Fluorescent Protein (CFP) and Yellow Fluorescent Protein (YFP).


Figure 2.8 Maximum FRET Response Capacity of DuoCalN and UniCalN under CaMWT Overexpression. (a) Maximum conformational change in response to ionomycin with DuoCalN in cells overexpresing CaMWT. Normalized FR level falls rapidly to 1 (90% dynamic change) in less than a minute and stays close to 1 for the duration of the experiment. At the bottom, the simultaneous calcium rise from around 100 nM to 4.5 M. Calcium rise occurs in two steps: initially increasing to about 1 M before slowly rising to the final steady-state level. (b) Conformational change in response to ionomycin for UniCalN. The FRET and calcium response parallel that of DuoCalN with 100% FR dynamic change.

The sensor output is the ratio FRET/CFP () , with maximum attainable ratio change of 25-50%. The authors subsequently deployed this sensor in neonatal ventricular myocytes, and detected spatiotemporal variations in PKA activity (). The genetically encoded sensor of CaMKII activation is constructed similarly to the CN sensors described here, CaMKIIα protein is sandwiched between CFP/YFP or GFP/RFP-based FRET pairs.  The sensor is based on the idea that Ca2+/CaM binding to CaMKII displaces the autoinhibitory domain and induces detectable conformational change  ADDIN EN.CITE () in the CaMKII dodecamer. Indeed, the authors observed a ~30% change in HeLa cells in response to ionomycin (Fig. 3 of  ADDIN EN.CITE ()). The sensor also responded to calcium spikes in hippocampal neurons. The sensor has also been deployed and demonstrated to respond to calcium transients in acutely isolated adult cardiomyocytes  ADDIN EN.CITE (). The currently available CN sensor is based on the conformational changes in NFAT protein following dephosphorylation by CN (). The construction of this sensor is based on sandwiching a portion of NFAT protein between CFP/YFP FRET pairs. The changes in FRET/CFP ratio is ~10-15% in response to ionomycin in HeLa cell. The FRET change is abolished by the application of CsA. 
  DuoCalN and UniCalN sensors () showcase a comparable if not improved dynamic range and kinetic response, and expand the genetically encoded sensor toolbox utilized for cellular resolution understanding of signaling pathways in space and time. The next section will describe a Fluorescence-based assay for calibrating the activity of the sensors by coupling the conformational FRET activation with NFATc1 nuclear translocation dynamics in HEK 293 cells. 

2.5 Coupling Conformational FRET Activation of the CN Sensors to Activity
Similar to the CaMKII sensor Camui  ADDIN EN.CITE (), DuoCalN and UniCalN are sensors of conformational activation state of CN.  It may not be apparent how this activation state is related to the actual phosphatase activity of CN, and whether biological conclusions drawn from DuoCalN and UniCalN readouts, would prove directly informative for the role of CN activation in different physiological and pathophysiological contexts. The currently available CN activity sensor () appears to exhibit slow kinetics and limited dynamic range. Moreover, it is not clear how conformational state of NFAT corresponds to CN enzymatic activity. To guide the use of NFAT in evaluating CN activity, it is crucial to review some of the hallmarks of NFAT biology. 
 The family of NFAT transcription factors consists of four CN-dependent members, NFATc1 (NFAT2), NFATc2 (NFAT1), NFATc3 (NFAT4), NFATc4 (NFAT3), and one CN-independent member NFAT5.  The CN-independent member of this group NFAT5 is activated by osmotic pressure changes (). The basic domain structure of NFAT is shown in Fig. 2.9a, with the two CN docking sites  ADDIN EN.CITE (; ; ) represented by the consensus motifs PXIXIT and LXVP (where ‘X’ denotes any amino acid), the DNA binding domain (DBD), and the domain that contains the 13 serine residues dephosphorylated by CN for full NFAT activation (). When calcium concentration is low, NFAT protein is in a hyperphosphorylated state and resides mainly in cytoplasm. The rise in calcium concentration activates CN, which in turn physically docks with and dephosphorylates NFAT, stripping off phosphates from up to 13 serine residues. Dephosphorylation exposes nuclear localizing signals (NLSs), and yields NFAT translocation into the cell nucleus. Once in the nucleus, NFAT is rephosphorylated by the kinases GSK3 and CK1 that results in its export back to the cytoplasm. Accordingly, the relative ratio of nuclear to cytoplasmic NFAT is a determinant of the relative contribution and competition between CN phosphatase activity and NFAT kinases.  It is thus feasible to investigate the coupling between CN sensor activation and activity by hypothesizing the existence of a nonlinear correlation between NFAT nuclear fraction and some measure of CN activation dynamics. Indeed, as will be discussed below, there is a nonlinear relationship between nuclear NFAT fraction and the area under the curve (integral) of the normalized sensor activation profile. 




After 1-2 hours, less than 10% of the cells treated with 10 M ionomycin responded with partial NFAT translocation. We then hypothesized that NFATc1 may require physiological temperatures near 37C for proper function and translocation. In fact, some previous studies did perform all experiments at 37C when investigating NFAT and NFB translocation  ADDIN EN.CITE (; ; ). Per our hypothesis, performing the translocation experiments on the confocal microscope with a mounted temperature-controlled chamber resulted in strong NFAT translocation in 100% of HEK 293 cells treated with 10 M ionomycin. Moreover, for our particular translocation assay, HEK 293 cells were better models than HeLa or Cos7, as their initial un-stimulated NFATc1 levels (assayed by the intensity of the red fluorescence in the nucleus) were much lower than in HeLa or Cos7 cells.  We observed suboptimal translocations (<10%) for temperatures less than 34C, which would translate into an ultra steep temperature dependence for NFATc1 nuclear translocation. 
  By simultaneously observing CFP, FRET, and mCherry channels, we were able to simultaneously evaluate sensor activation and NFATc1 translocation following the application of thapsigargin. Previous experiments with Indo-1 had taught us that varying the external calcium from 0 to 400 M could produce variable amplitude calcium transients. Therefore for the translocation experiments, the cells were placed in Tyrode solution containing calcium concentrations in the range of 0-400 M to obtain calcium transients of variable amplitudes, and thus variable sensor activation. The cells were imaged every 30 s, and 1M thapsigargin were added to the solution after 10-15 minutes of baseline imaging. This initial delay in imaging was included to obtain a clear fluorescence baseline. NFATc1 nuclear translocation dynamics was calculated using the ratio of nuclear red fluorescence to the whole-cell red fluorescence,  (Figs. 2.10c and 2.10d). The sensor response was quantified by computing the normalized change in R=FRET/CFP (). To deduce correlation parameters, we selected data from cells that had low initial nuclear NFAT fraction (<0.15) to retain the full range of NFAT response to CN activation. The change in total nuclear NFAT,  was correlated with the area under the curve of () as shown in Fig. 2.10g.  A cell with small sensor activation results in modest NFAT translocation (Fig. 2.10a), while a cell with large and broad amplitude sensor activation, leads to robust and strong NFAT nuclear accumulation (Fig. 2.10b).  It is also instructive to note that the initial event in NFAT nuclear enrichment is the appearance of highly fluorescent red puncta in the nucleus that could potentially represent the sites of NFATc1 binding to cellular DNA.  
  Number of new insights are gained by close inspection of the coupling between CN activation and NFAT translocation dynamics in Fig. 2.10 and Fig. 2.11.  In Fig. 2.10c transient sensor activation with duration of 2 minutes is sufficient to result in NFAT dephosphorylation and nuclear import. It is interesting to note that while the sensor activation transient declines to near basal level after 1.5 minutes, the fraction of nuclear NFAT continues to rise. Nuclear NFAT accumulation reaches the steady-state value of 0.3 after ~9 minutes. Similarly in Fig. 2.11c (for UniCalN sensor), NFATc1 nuclear import continues long after the abatement of the CN activation signal. These results are consistent with recent mathematical modeling work positing that high level of cooperativity between the 13 serine sites on NFAT leads to a switch like behavior in NFAT activation dynamics  ADDIN EN.CITE (, ). Our results suggest that once a sufficient fraction of NFAT sites are dephosphorylated, the nuclear import is inevitable even after the fall of calcium transient and CN activation. The NFAT translocation dynamics in HEK 293 cells is also consistent with the data from T lymphocytes and Jurkat T cells. In T cells, TCR engagement with antigen induces calcium transients with a period of about 100s () that is sufficient to activate NFAT translocation and subsequent target gene induction. In Jurkat T cells, a single calcium transient with amplitude of 1 M and  duration of 3 minutes  leads to near-complete NFAT translocation that persists long after the decay of  the initiating calcium signal  ADDIN EN.CITE ().  
  An important aspect of the translocation data pertaining to the kinetics of NFAT translocation is that  the export rate of NFAT (biologically determined by nuclear kinases such as GSK3 and CK1) is extremely slow. In fact, in the experiments discussed here, no significant nuclear export was observed even after 1 hour of imaging. 
 A remarkable nonlinear correlation is discovered for both DuoCalN and UniCalN (Figs. 2.10g and 2.11g) relating the amount of NFAT import,  to the temporal integral of the normalized CN activation, :  for DuoCalN and  for UniCalN. Note also that the steady-state nuclear NFAT never reaches value of 1. There are two possible reasons for this. First, the calcium transients elicited by thapsigargin might not have the large enough amplitude and long enough duration to fully activate all the available pool of CN. Second, the concentratation of expressed CN sensor might not be sufficient to dephosphorylate all the available NFAT pool. In our experiments, the maximum attainable NFAT nuclear fraction was 0.8 achieved by 1 M ionomycin in the presence of 2 mM external calcium. The use of ionomycin for activation calibration was abandoned as ionomycin had detrimental effects on the cellular morphology and viability. Ionomycin was also found to be inefficient for eliciting calcium transients of variable amplitudes. According to the calibration equations, in order to increase nuclear NFAT by 50% of its maximum value (0.45/2), CN needs to be activated to such an extent as to generate the area under the curve of  = 6.24s. Suppose that the shape of the CN activation curve can be approximated as a triangle. The temporal integral can then be computed by the area of the triangle, taking into account the duration and the amplitude of the activation signal: 

The maximum possible normalized sensor activation amplitude in HEK 293 cells under confocal microscopy was determined by the application of 10 M ionomycin, and the value was about 0.2 (average value observed in ~10 cells).  This implies that: . This simple calculation illustrates that effective activation of NFAT requires physiological calcium signals with duration of 10s of seconds  ADDIN EN.CITE (; ; ; ; ).  This calculation also predicts that NFAT activation during single calcium transient is negligible in excitable cells such as cardiomyocytes where the duration of the calcium transient is at most 500 ms under physiological conditions. 
 To summarize: the UV- based calcium dye Indo-1 was utilized to concurrently image calcium concentration changes with FRET measurements. Plotting normalized FR, versus calcium concentration [Ca](M) yielded a Hill equation with the Hill coefficient of nHill=3.8, and Kd=300 nM, for both DuoCalN and UniCalN () which implied that least 4 calcium ions are necessary for CN activation, and that cellular calcium concentration of 300 nM result in 50% activation of the sensor. Further, by co- expressing the sensors and WT CaM, the maximum sensor response was found to be limited by CaMTotal. These findings are quantitatively consistent with previous in vitro biochemical assays () that found a Hill equation with the Hill coefficient of 3 for the dependence of CN activity with [Ca].  In different set of experiments correlating NFATc1 nuclear translocation with sensor activation, the integral of CN activation was found to be correlated with the total NFATc1 nuclear translocation. For both sensor the empirically determined equation was in the form ΔFn=Ftot (1-exp(-Q/9)) with the maximum recrutable NFAT Ftot was 0.42 for DuoCalN and 0.45 for UniCalN. This equation is easily seen to be the solution of the following differential equation: 
dFn(t)/dt= (1/9) Rsensor(t) (Ftot-Fn) = kin(t) (Ftot-F0), where kin(t) is the rate constant for NFAT nuclear accumulation as shown in Fig. 2.10 and Fig. 2.11. This means that
kin(t)= (1/9) (-ΔR/R0). This remarkable yet simple relation implies that the normalized sensor output is linearly related to the rate constant for the NFAT nuclear important. In other words, this relations strongly hints that the conformational activation is linearly dependent on the activity assayed by the rate of NFAT nuclear import. Thus, the normalize sensor output (-ΔR/R0) is not only a measure conformational activation, but also of CN activity in cells.   









Figure 2.11 Coupling UniCalN Sensor Activation to its Activity via NFATc1 Nuclear Translocation. (a)  Time-lapse imaging of mCherry-NFAT nuclear import in a cell placed in calcium free solution buffered by 1 mM EGTA. The outline of the nucleus is drawn. (b) CFP and FRET channels for UniCalN distribution, (c) Thapsigargin  leads to partial NFAT enrichment in the nucleus (Fnuc=NFATnuc/NFATtotal ~0.4, top) and modest activation of the sensor (Rsensor=FRET/CFP, bottom) that returns to the baseline after 2 minutes. (d) Time-lapse images of NFAT  translocation for a cell in 200 M calcium. (e) CFP and FRET channels denoting sensor expression and distribution. (f) Thapsigargin induces robust NFAT translocation (Fnuc~0.6, top) with concurrent broad sensor activation profile that lasts for ~5 minutes. (g) Calibration curve correlating the total change in nuclear NFAT vs. the activation integral. The equation describing the calibration is ∆Fnuc=0.45 (1-exp(-Q/9)). This empirical equation is the solution of the ODE dFn/dt=kin(t)(Ftot-Fn) where the rate constant of NFAT nuclear accumulation k​in, is linearly related to the normalized sensor response Rsensor(t) and Ftot is the total recruitable NFAT  fraction. This implies that the readout of the sensor is linearly related to the acitvitiy assayed by NFAT nuclear accumulation rate. 


2.6 DuoCalN and UniCalN Deployment in Cardiomyocytes
As discussed earlier in this chapter, CN is the only phosphatase that is activated directly by calcium. It is not only prominent in normal cardiac development and function, but also as a central regulator of the cardiac hypertrophic response. The use of genetically encoded FRET-based kinase sensors have provided novel and remarkable insights into the function and activity of these kinases in live cardiomyocytes  ADDIN EN.CITE (; ). In fact the use of the CaMKII sensor, Camui, was instrumental in identifying a previously unknown link between diabetes and cardiac dysfunction  ADDIN EN.CITE (). Likewise, it is our hope that the use of DuoCalN and UniCalN will aid in better understanding of CN dynamics and function in normal and pathological states of cardiomyocytes. 
   The first step in transiently expressing the sensor in cardiomyocytes is to use an adenoviral transduction system. The Cre-Lox based adenoviral transduction methodology is well established and detailed elsewhere  ADDIN EN.CITE (; ; ). Briefly, the first step is to clone the constructs into a pADLOX vector (). VENUS was PCR amplified and subcloned in XbaI/EcoRI sites of the pADLOX vector to generate PADLOX-VEN vector. PCR was then used to amplify CER-CalNB-FQGPGP2A-CalNA (DuoCalN) or CER-CalNB-GSGP2AM-CalNA (UniCalN) using SalI and XbaI sites and to generate SalI-DuoCalN-EcoRI or SalI- UniCalN- EcoRI respectively as shown in Fig. 2.12. The constructs in pADLOX were then transfected along with the  shuttle vector to package the sensor into viral particles in HEK 293 cells stably expressing Cre8 recombinase (Cre8 cells). After a few rounds of expansion in Cre8 cells, the viral particles are purified using CsCl column.  The density of the viral particles for DuoCalN sensor was  particles/l and for the UniCalN sensor was  particle/l. 
  To evaluate the response of the sensor in developing neonatal myocytes, neonatal rat ventricular myocytes were isolated using the standard protocols  ADDIN EN.CITE (; ). The viral particles carrying the sensor constructs were then added to the media 24 hours prior to imaging. On the day of imaging, the cells are washed once with warmed PBS, and fresh media is added.  Fig. 2.13 shows the expression of DuoCalN and UniCalN in NRVMs. The sensors are uniformly distributed in cytoplasm and are excluded from the nucleus. On the imaging day, NRVMs were loaded with Indo-1 dye and electrically stimulated with standard grass simulator with stimulating electrodes positioned within 1-2 mm of each other. The voltage amplitude for efficient NRVM field stimulation was in the range of 10 – 20 V with duration of 20-50 ms. Mechanical contraction of cells under the microscope following single stimulation pulse indicated successful field stimulation. Data from each wavelength (FRET, CFP, Indo405, and then Indo485 channels) were gathered in series as shown by the diagram in Fig. 2.14a. A delay of 12 s was inserted to ensure the return to basal state. Indo-1 traces were lowpass filtered with a 20 Hz cutoff frequency, while the same filtering algorithm was performed on individual CFP and FRET traces with 5 Hz cutoff. It is important to note that this filtering did not alter the FRET response of the sensors, and the transient decrease in FRET and the rise in CFP signals (Fig. 2.14 b) were clearly identifiable from the raw traces alone.  

 
Figure 2.12 DuoCalN and UniCalN in pADLOX. (a) Plasmid map of the pADLOX plasmid employed in adenoviral vector construction. Molecular cloning site (MCS) is shown along with the SalI, XbaI, and EcoRI sites used in cloning the sensors into the plasmid (b) DuoCalN in pADLOX. Venus is cloned in with XbaI/EcoRI sites (with the stop codon). The rest of the construct cloned in into SalI/XbaI sites. The domain structure shown at the bottom.  On the right, UniCalN is cloned in similarly with the corresponding domain structure at the bottom.

The utility of the ‘normal’ protocol for stimulation is shown in Fig. 2.14b, by an exemplar cell (expressing DuoCalN) paced at 0.2 Hz. The left column shows the raw data for the four channels gathered in series (Fig. 2.14b) that highlights the fluorescence bleaching that occurs during the imaging process. On the right hand column of Fig. 2.14b, the bleach corrected versions of the raw traces (obtained by a continuous fit to the baseline decay) are shown. Since the data are gathered in series, occasional ectopic contractions occur in NRVMs that activate the sensor as is apparent in the initial phase of the CFP signal. To clearly visualize and quantify the on and off kinetics of the sensor from the quiescent sate, the ‘island’ mode protocol was developed. The island protocol is described by the diagram in Fig. 2.15a. Under this protocol, electrical stimulation (at a specified pacing rate) is performed for a specified duration (τisland) between the two silent periods with durations denoted by τ1 and τ2. The 0.5 Hz paced exemplar cell exhibiting the utility of the island protocol is shown in Fig. 2.15b. Similar bleach correction on the raw traces (left column) was performed to obtain the traces on the right. Also note that the traces in Fig. 2.15b demonstrate the enormous utility and advantage of our ratiometric sensor in automatically correcting for motion artifacts. Individual CFP and FRET signal traces have large amplitude and fast downward spikes overlaid on a slower varying signal. These fast fluctuations are superimposed onto the real FRET-based changes caused by CN conformational activation. Remarkably, the ratio R=FRET/CFP (red trace) corrects for the motion induced fluorescence fluctuations, and recovers the real FRET-based signal that shows a much slower dynamic change. This feature of our ratiometric sensors alleviates the need for applying chemical compounds that block cardiac contraction machinery. Once the stimulation protocols are established, it is crucial to identify and extract parameters from the fluorescence traces that can then be utilized to investigate variations in pacing frequency dependence of different cell types, and cells at specific developmental stages (neonatal vs. adult). 


Figure 2.13 DuoCalN and UniCalN Expression and Distribution in NRVM Cells. (a)DuoCalN expression and distribution in NRVMs with CFP channel (top) and FRET channel (bottom). (b) UniCalN distribution in NRVMs with CFP channel (top) and FRET channel (bottom). 


Figure 2.14 Normal Stimulation Protocol for Cardiomyocytes. (a) Computer controlled pacing begins at t=0 and continues for a specific amount of time with the shutter open to gather data everty 1-2 ms. The shutter closes and a delay of 12s or more is introduced before the next wavelength. (b) An NRVM cells expressing DuoCalN is paced at 0.2 Hz. The left four panels show the indo-1 ratio (black), FRET/CFP (red), FRET (green), and CFP (blue) signals respectively from the top. Note the appearance of ectopic CN activation in the CFP (blue) signal as a result of arrhymogenic NRVM contraction that may occasionally occur without any external stimulation. The right-hand panel depicts the same traces divided by the  bleach curve (dashed line).  Bleach correction is performed only on FRET and CFP raw traces. The amplitude of the sensor response (red, right column) is determined by a line fit (dashed grey line).


Figure 2.15 Island Mode Stimulation Protocol for NRVMs. (a) There is a delay of duration τ1 before the pacing begins. The shutter opens to gather data every 1-2 ms. After τisland seconds, pacing stop for τ2 seconds. Delay of 12 s is introduced before the beginning of the next series. The shutter is open throughout the island mode for  seconds. (b) The raw data for a cell expressing DuoCalN, and paced at 0.5 Hz. Note the bleaching of CFP (blue) and FRET (green) signals with the the fitted lin (grey dashed). On the right hand side, the same data, but bleach corrected. Large downward motion-induced fluctuations are clearly visible in CFP (blue) and FRET (green) signals, but not in the ratio (red signal). 


Figure 2.16 Amplitude (Amp) and Kinetic (t1/2) Parameters for Quantifying CN Dynamics in Cardiac Myocytes. Electrical stimulation begins at 10s time point and continues for 30s before turning off for additional 15s. The fit to the sensor ratio (grey, dashed) is shown for an NRVM cell expressing DuoCalN. The fitted values are t1/2=2.29s and Amp=0.03.

We have identified two such parameters: one is the normalized amplitude of the sensor FRET ratio (Rsensor, Fig. 2.14b and Fig. 2.15b) and the second is the half time to full activation from the quiescent state (t1/2) during the island mode stimulation protocol. Fig. 2.16 outlines the general methodology for extracting these parameters from an actual FRET ratio trace. As we will see in the next section, these two parameters have different frequency-dependent profiles in NRVMs and AGPVMs, and quantify the differential activation of CN in neonatal versus adult myocytes.

2.7 CN Dynamics in Neonatal versus Adult Cardiomyocytes
The sensors developed here showed great promise in elucidating CN conformational activation in response to calcium elevation in HEK 293 cells. The sensors also expressed well when placed in a viral vector, and added to NRVM cultures (Fig. 2.13). No toxicity was observed for up to 2 days of continuous sensor expression. In this section, we attempt to understand the pacing frequency dependence of CN activation in cardiomyocytes. This would showcase the first experimental observation of a phosphatase activation dynamics in live excitable cells, and the first observation of differential CN activation in neonatal versus adult myocytes. This may provide a rationale for physiological role of CN during development, and its subsequent pathological role in adult heart. Each sensor is deployed in NRVMs and AGPVMs and amplitudes and time constants are measured for each cell at different pacing frequencies. Fig. 2.17 illustrates the behavior in an exemplar NRVM cell expressing DuoCalN. The data presented here are for cells being stimulated with a single pulse (0 Hz, Fig. 2.17a), 0.2 Hz pacing (Fig. 2.17b), 0.5 Hz pacing (Fig. 2.17c), and 1 Hz pacing (Fig. 2.17d). The continuous line fits (Fig. 2.17a-d second row, solid black lines) to the activation rise from quiescent basal state are also shown. The grey line fits to the decay phase of the sensor activation are also shown (Fig. 2.17 a-d second row). In NRVMs, CN is prone to fast kinetic activation during single twitch calcium transients as demonstrated in Fig. 2.17a. The population data at each frequency are also shown in Fig. 2.17e where normalized amplitudes (Amp) (see Fig. 2.16 for explanation) are plotted against different pacing frequencies. The Amp versus frequency profile supports the idea that CN in NRVMs is readily activatable. A quantitative measure of this statement is given by the zero slope of the Amp versus frequency curve: . 


Figure 2.17 Frequency Dependence of DuoCalN Dynamics in NRVMs. (a) Single pulse of calcium (~50% amplitude) leads to decrease in FRET ratio of 0.04 (red). FRET signal decreases by 0.02 (green), while the CFP signal increases by about 0.02 (blue signal). (b)  0.2 Hz pacing activates the sensor to about 0.045 with simultaneous decrease in FRET signal (green) and increase in CFP. (c) 0.5 Hz pacing further activates the sensor by about 0.045. Motion induced fluctuations are present in FRET (green) and CFP (blue) signals, while being absent in the  ratio (red). (d) 1 Hz pacing leads to rapid activation of the sensor to 0.05 (red) with half time to activation, t1/2, of around 2s with simultaneous decrease in FRET (green) and increase in CFP (blue) signal. (e) Amplitude versus frequency plot of DuoCalN showing a slow increasing nearly flat distribution around 0.05 with . (f) Half time to activation from quiescent state in response to 0.5 Hz and 1 Hz stimulation is around 2s. 
 
Another crucial parameter is t1/2 of the sensor in the island mode protocol (see Fig. 2.15a for explanation of the island protocol). Similar to the amplitude parameter, t1/2 has a sigmoidal shape with the steady-state value achieved at 1 Hz (~2 s). The implications of this plot will become clear when it is compared with the same plot for AGPVMs. We should again note the utility of the ratiometric character of this sensor in alleviating the motion artifacts produced by often wild myocyte mechanical contractions. 
  Similar results are obtained for the UniCalN CN sensor as demonstrated by Fig. 2.18.  The amplitude versus frequency profile is nearly flat (, Fig. 2.18e) confirming that both constructs are readily activatable in NRVMs in 0 Hz–1 Hz frequency range. The slope of t1/2 versus frequency for UniCalN seems to be lower than that of DuoCalN (Fig. 2.18f compared with Fig. 2.17f). A possible explanation for this difference is that placing a physical linker between the two CN subunits may put a strain on the structure of the CN complex, and reduce the speed and versatility of the conformational changes. It is in fact remarkable and surprising that the maximum amplitude at 1 Hz is the same (~0.05) for both sensor types. This similarity between DuoCalN and UniCalN implies that the mutant P2A (P2AM) can be quite an effective and efficient linker to be deployed in other FRET- based genetically encoded sensors, where the problem of linker design is often a major obstacle in achieving the full potential of  sensors in terms of speed and FRET dynamic range. 
  To gauge the extent of CN activity in NRVMs in response to electrical pacing, it would also be instructive to estimate the extent of NFAT translocation for a given CN activation transient. This can be done with the calibration equations outlined in Fig. 2.10 and Fig. 2.11.  The single calcium transient has duration of about 5 seconds and amplitude of 0.05. The area under the curve is then ~0.25/2 assuming a triangular shape for the transient. The amount of NFAT translocation is then estimated to be ΔNFAT=0.0033, which is negligible. By assuming that NFAT nuclear export rate in NRVMS is similar to HEK 293 and Jurkat T cells and hence negligible, this implies that at least 200 pulses are necessary to induce 66% NFAT translocation. For 0.2 Hz and 1 Hz pacing rates, the area under the curve can be estimated by assuming a rectangular signal shape as is apparent from Fig. 2.17 and Fig. 2.18. By this assumption we can estimate the duration of 1 Hz train necessary for 50% NFAT translocation. This is easily estimated to be about Tpacing=Ln(2)/0.05~14s,  predicting that complete NFAT translocation would occur for the exemplar cells in Fig. 2.17 and Fig. 2.18.  The heart rate for 2-3 day old rat pups is around 320 bpm or 5 Hz. For this pacing rate, our data predict that in the absence of endogenous negative regulators of NFAT translocation, NFAT would always be nuclear in beating NRVMs. This is indeed consistent with results of other groups studying NFAT translocation in NRVMs. In fact, one group of investigators has identified CaMKII as a negative regulator of NFAT translocation in NRVMS  ADDIN EN.CITE ().  In their experiments, under control quiescent conditions 12% of the cells already had complete GFP tagged nuclear NFATc3, but after transducing the cells with a dominant negative form of CaMKII the fraction of the cells with complete nuclear localized NFATc3 increased to 50%  ADDIN EN.CITE () under the same culture conditions. 




Figure 2.18 Frequency Dependence of UniCalN Dynamics in NRVMs. (a) Single pulse of calcium (~80% amplitude) leads to decrease in FRET ratio by 0.085 (red). FRET signal decreases by 0.02 (green), while the CFP signal increases by about 0.1 (blue signal). (b) 0.2 Hz pacing activates the sensor to about 0.1 with simultaneous decrease in FRET signal (green) and increase in CFP. (c) 0.5Hz pacing rapidly activates the sensor to about 0.05. (d) 1Hz pacing leads to rapid activation of the sensor to 0.05 (red) with half time to activation of around 2sec with simultaneous decrease in FRET (green) and increase in CFP (blue) signal. (e) Amplitude versus frequency plot of UniCalN showing a slow increasing nearly flat distribution around 0.05,  .(f)  Half time to activation from quiescent state is around 1.5sec .

Note that the sensors are predominantly localized to the z-lines (sarcolemmal regions) where the calcium channels and calcium release machinery (RyR2 receptors) are located in close (~nm) proximity. This is consistent with CN localization to calcium channels by the scaffolding AKAP proteins  ADDIN EN.CITE (; ). The frequency dependence of CN activation in AGPVMs has different features from that in NRVMs as illustrated in Fig. 2.20 for DuoCalN and Fig. 2.21 for UniCalN.  Single pulses (0 Hz) of calcium do not appretiably activate the sensor which is in stark contrast to NRVMs (Fig. 2. 20a compared with Fig. 2.17a).  0.2 Hz pacing also had a similar effect on the sensor, with little activation of the sensor. However, increasing the pacing to 0.5 Hz and 1Hz resulted in cumulative activation of the sensor that closely followed the elevation of the intracellular calcium (Fig. 2.20c and Fig. 2.20 d). Fig. 2.20e shows the population distribution of the sensor amplitudes (Amp) versus the pacing frequencies. In the same plot, amp versus frequency profile of AGPVMs is contrasted with that of NRVMs (solid blue line). While in NRVMs the line is flat with zero slope (meaning that CN is activatable in all frequencies), in AGPVMs the activation occurs appretiably only at higher frequencies of 0.5 Hz and 1 Hz with the slope of . Another important observation is that the time constant t1/2 (defined in Fig. 2.16) is 5-fold smaller in AGPVMs (~5sec at 0.5 Hz and 10sec at 1 Hz). Note that interestingly the maximal amplitude achieved in AGPVMs by the sensor is the same as NRVMs (Amp value at 1Hz). Similar results are obtained for UniCalN sensor expressed in AGPVMs as demonstrated by Fig. 2.21. Likewise, there is no sensor response to single pulse or 0.2 Hz pacing, while the activation peaks at 1 Hz pacing. Accordingly, it is expected that NFAT is fully localized to the nucleus in AGPVMs in response to 0.5 Hz and 1Hz pacing rates. In fact, recent results in the literature show that there is a gradual increase in the fraction of nuclear NFAT from 24% (basal quiescent), to 45% (at 0.5Hz pacing), and eventually to 60% (1Hz pacing) in acutely isolated adult feline ventricular myocytes (AFVMs)  ADDIN EN.CITE (). 







Figure 2.20. Frequency Dependence of  DuoCalN Dynamics in AGPVMs. (a) single pulse of calcium does not activate the sensor. Normalized CFP (blue), FRET(green), and the ratio(red) are unresponsive. (b) 0.2 Hz train fails to elicit any response in the sensor.(c) 0.5 Hz trains lead to calcium summation that in turn activates the sensor by about 4%.(c) 1Hz pacing for 50s leads to robust increase in sensor activation (red) with subsequent decline to the basal level after the pacing is turned off. The sensor response is similarly around 4%. (e) Amplitude vs. frequency distribution for AGPVMs (red filled circles and solid red line , n=4-10 cells for each point) show a gradual rise in amplitude with  . In contrast, the corresponding NRVM distribution curve (solid blue) is nearly flat at around 0.05. (f) The half-time to activation from quiescent state in AGPVMs is around 5s in 0.5 Hz and 10s at 1 Hz (red filled circles and red line), about 5 times slower than that of NRVMs (solid blue curve).






Figure 2.21 Frequency Dependence of UniCalN Dynamics in AGPVMs. (a) Single pulse of  calcium does not activate the sensor. (b) 0.2 Hz calcium train fails to elicit any response in the sensor. (c) 0.5 Hz train leads to negligible sensor activation in this particular cell. (d)1 Hz pacing for 50s leads to robust increase in sensor activation (red) by 0.05 with subsequent decline to the basal level after the pacing is turned off. (e)Amplitude vs. frequency distribution in AGPVMs (red filled circles and solid red line, n=4-10 cells for each point) show a gradual rise in amplitude with , In contrast, the corresponding NRVM distribution curve (solid blue) is flat at around 0.05. (f) The half-time to activation from quiescent state in AGPVMs is around 5s in 0.5 Hz and 10s at 1Hz (red filled circles and red line) about 5 times slower than that of NRVMs (solid blue curve). (g) 5 mM caffeine elicits robust sensor response in NRVMs (0.06 for DuoCalN and 0.08 for UniCalN) and AGPVMs (0.07 for DuoCalN and 0.05 for UniCalN). The data are averages from 3-5 cells.


The caffeine response of the sensor amplitudes was quantitatively comparable in both NRVMs and AGPVMs (~0.05-0.09), and was comparable to that achieved by 1 Hz pacing in both cell types (~0.05). 
  To summarize the findings of this section, both of our CN sensors were deployed in NRVMs and AGPVMs. In NRVMs, CN readily responded to single twitch calcium transients. At 1Hz it required 2 seconds for the sensor to reach half-maximum activation from the basal quiescent state. In contrast, in AGPVMs, CN was unresponsive to single pulse and low frequency pacing of 0.2 Hz; however, the amplitudes began to grow at 0.5 Hz pacing. Pacing at 1 Hz was necessary for efficient activation of CN sensors. The half time to activation or t1/2 was around 10 seconds, 5-fold slower than that of NRVMs. 
  In the next section, we will apply an empirically based mathematical model to understand the underlying dynamics of CN in NRVMs and AGPVMs. Mathematical analysis of the data will aid in formulating concrete ideas and hypothesis regarding differential activation of CN in NRVMs and AGPVMs, and suggest new avenues for further experiments. In fact, we will see that the model predicts that fluctuations in free CaM concentration may tune CN activation level and kinetics in adult cardiac myocytes, analogous to the role of apoCaM in tuning the CDI of CaV1.3 L- type channels in the brain. 

2.8	Mathematical Analaysis of CN Dynamics in Cardiomyocytes 


In order to gain a deeper understanding of the underlying dynamics of biological systems, it is crucial to construct predictive and constrained mathematical models. Without the aid of mathematical models, it would be very difficult to predict the outcome of nonlinear interactions in biological systems. CN/NFAT pathway exudes the nonlinearity inherent in many signaling pathways. Nonlinearities enter the system in different stages of CN activation. Nonlinearity is involved in the binding of Ca2+ ions to C- and N- lobes of CaM, Ca2+ binding to the C- lobe of CalNB subunit,  and the subsequent binding of Ca2+/CaM to CN. It is therefore essential to formally describe these kinetic steps with a mathematical model and constrain the parameters of the model by fitting the sensor data. 
Indeed, one powerful impetus for developing genetically encoded sensor technology is their utility in obtaining precise temporal and spatial information regarding the activation states and activity of signaling proteins. This new window into the inner workings of signaling pathways coupled with the power of mathematical modeling allows for an unprecedented view of   signaling processes that have long eluded traditional biochemical approaches. In the case of CN/ NFAT pathways, researchers have already made in roads in constructing large scale systems models that capture the essential dynamics of the molecular interactions  ADDIN EN.CITE (; ; ; ; ; ). The application of these models is limited in the absence of suitable genetically encoded sensors. By utilizing these sensors, one can obtain subcellular resolution temporal and spatial information in live cell. 
  The most comprehensive model of CN activation pathway to our knowledge was constructed by Dr. Jeffery Saucerman and Dr. Donald Bers who surveyed the existing biochemical and qualitative data to model CN activation in different compartments of the adult cardiac myocytes (cytoplasm, sarcolemmal regions, and cytoplasm) ().  In their model they include 3.5dyadic and 3 nM cytoplasmic pool of CN. The main biological conclusion from their simulations is that dyadic CN is always active  in a beating cardiac myocyte even with 1 Hz pacing . In contrast, cytoplasmic CN gets activated only at pacing rates of 4 Hz and higher , and acts much like a low pass filter. These conclusions are based on the use of very small koff value of 0.001 s-1 for the unbinding of Ca2+/CaM from CN. According to our data, CN inactivation roughly follows that of calcium decline and thus the off kinetics of Ca2+/CaM departure from CN is expected to be in the order of seconds (in fact koff=1 s-1 according to the model fit to the data described below).  Even with this faster off kinetics, dyadic CN is still expected to remain fully active from beat-to-beat in a normally beating adult guinea pig heart that beats at a rate of around  200-250 bpm (3-4 Hz). However, according to our sensor data, the active dyadic CN conclusion would change for slower beating rates. 
 The approach taken in this section is to construct a minimal model that captures the essential known biology and experimentally verified aspects of CN activation. We assume that ~10% of activity is due to calcium binding to CalNB subunit, and that the rest of the contribution to CN activation (~90%) is due to Ca+2/CaM binding to CalNA  ADDIN EN.CITE (; ; ; ; ) (Fig.2.1b).  The kinetic pathways describing the steps involved in CN activations are:

          
Ca2CaM = CaM with 2 Ca2+ ions bound.
Ca4CaM = CaM with 4 Ca2+ ions bound.
Ca2CaN = CN with 2 Ca2+ prebound to the high affinity sites on the N- lobe of CalNB.
Ca4CaN = CN with 4 Ca2+ bound to CalNB (fully Ca2+ charged CN).
Ca4CaMCa4CaN= Activated CN with Ca2+/CaM bound and fully Ca2+ charged CalNB.
Eqs. (1)-(2) describe the binding of Ca2+ ions to each lobe of CaM. Eq. (3) denotes the binding of 2 Ca2+ ions to low affinity sites on the C- lobe of CalNB, and Eq. (4) describes the binding of Ca+2/CaM to CN that results in full activation. The activation of the sensor is fitted using the following variable defined by a linear combination of the fraction of calcified CN (Ca4CaN in the kinetic scheme) and Ca2+/CaM-bound (Ca4CaMCa4CaN) form of CN: 














Where C1 and C2 are constants of the system (11)-(14) given by:


Given that the initial (t=0) cytoplasmic abundance of Ca- bound forms of CaM and CN are basically negligible,  and  denote the initial free CaM () and free CN  (). Note that CN complex is already bound to 2 Ca2+ ions in its CalNB subunit in basal calcium concentrations (50-100nM).  The values for the kinetic constants are based on the values used in Saucerman- Bers model (). With other parameters modified to best fit our DuoCalN sensor dynamic data​[9]​. 

























	Variable from cell to cell 	Fit
	1(NRVM), 0.46 (AGPVM)	

Combining mathematical modeling with the dynamic CN sensor data has provided intriguing biological insights into dynamics of CN in neonatal versus adult cardiomyocytes. Because a single kinetic model fits all the cellular data paced at varying frequencies, the underlying biology of CN activation is the same in neonatal versus adult myocytes. The simplest hypothesis that emerges from the modeling exercise is the remarkable idea that the main difference in CN response in NRVMs and AGPVMs is the concentration of free CaM. This is consistent with the biology of developing cells such as NRVMs. These cells are at a developmental stage, where the constitutive physiological -


Figure 2.23 Fitting the Computational Model to DuoCalN Dynamics in NRVMs and AGPVMs Paced at Different Frequencies. The calcium transients (not shown) are fed into the ODE model and the numerical solutions (solid red, see Eq. 5) are fit to the experimental activation data of DuoCalN. For NRVMs (a-d) (a) Model fits to a single pulse of CN activation  with 30 nM free CaM. (b) 0.2 Hz pacing leads to a strong response. The computed CaM level is [CaMfree]=40 nM. (c) 0.5 Hz summation response in CN sensor is fit with the model with CaM=120 nM. (d) 1 Hz pacing results in strong CN activation which is fit with the model in both on and off phases of the activation curve. The free CaM=70 nM.  For AGPVMs (e-h) (e) Single pulse fails to elicit any response and is captured by the model with 30 nM free CaM (f) A non responsive cell paced at 0.2 Hz is also fit with the model (g) A cell paced at 0.5 Hz is fit with the model. The activation kinetics (6s) and the final amplitude (.04) are captured by the computational fit. (h) A cell paced at 1 Hz for 30s. The model correctly follows the on and off phases of the sensor, (i) Sensor expression is evaluated by the initial pre-pacing CFP fluorescence level. For NRVMs, mean CFP0 level is (n=10), which is 2.16 times higher than its value in AGPVMs (, n=10), (j) Computed CaM levels in NRVMs (mean value 250 nM, n=20) compared to AGPVMs (mean value 100 nM, n=8).


Figure 2.24 CaM Tuning of CN Dynamics in AGPVMs. (a) AGPVM cell expressing DuoCalN. The cell is paced at 1Hz in island mode for 15s. The models with free CaM=30 nM. CaM is computationally varied from 5 to 95 nM. The curves shown correspond to CaM levels of 5, 15, 30, 75, and 95 nM from bottom to the top.  The initial activation kinetics increases as CaM is elevated. The steady-state sensor amplitude rises as well. 2.5-fold increase in the fitted CaM level (30 nM for the third red line from the bottom to the blue line corresponding to 75 nM of free CaM) nearly doubles the amplitude and the kinetics of the rise phase (b) Another AGPVM cell paced at 0.5 Hz. Sensor is non-responsive. CaM is varied from 10 nM (lowest curve) to 100 nM (highest curve). The curves shown correspond to 10, 20, 30, 50, 70, and 100 nM free CaM concentrations.  2.5 fold increase from 30nM to 70nM is predicted to result in detectable FRET response. Both activation amplitudes and kinetics  increase in response to free CaM elevation

activation of CN/NFAT is necessary for efficient development and physiological cardiac growth. In AGPVMs the activation of CN/NFAT is hypertrophic and these cells need to tightly control limit the activation of pathological hypertrophic genes and one way that this is achieved is by limiting the pool of free CaM (Fig. 2.23j and Fig. 2.24b).  

2.9	Discussion
To summarize the results obtained in this section, both DuoCalN and UniCalN express in NRVMs and AGPVMs without detectable toxicity for up to 36 hours.  Expression in NRVMs is cytopalsmic and uniform while in AGPVMs the expression is sarcolemmally enriched consistent with CN biology in acute cardiomyocytes (Fig. 2.14 and 2.19). Both DuoCalN and UniCalN show FRET change in response to twitch calcium transients in NRVMs with activation summation when paced at 0.5Hz and 1Hz. In contrast to NRVMs, the sensors do not respond in AGPVMs at pacing rates of 0.2Hz or lower. The activation begins to emerge when adult cells are paced at 0.5Hz and 1Hz. The initial kinetics of activation from the quiescent state is much slower in AGPVMs when compared to that in NRVMs (5- fold slower, Fig.2.20 and Fig.2.21). Moreover, the slope of the Amplitude versus frequency is drastically different in each cell type.  
In NRVMs, the distribution is flat implying that, while in AGPVMs . Moreover, the application of caffeine results in comparable sensor activation (amplitudes of about 0.06-0.08) in both NRVMs and AGPVMs (Fig. 2.21e). Fig. 2.25 summarizes the differences in parameters of CN activation between NRVM and AGPVMs.  
 The mathematical model constructed in this section was able to fit the sensor data in both NRVM and AGPVMs in wide range of pacing frequencies (Fig. 2.23a-h). The computed mean free CaM concentration in NRVMs was ~250 nM while the corresponding mean concentration in AGPVMs was ~100 nM. Further, Computational modeling predicted that CaM overexpression would transform AGPVMs into NRVM- like cells in terms of their CN activation properties. It also proposed a mechanism by which fluctuations in cellular free CaM can modulate and tune CN activation amplitude and kinetics (Fig. 2.24a and Fig. 2.24b) much like the apoCaM tuning of CDI in CaV1.3 discussed in chapter 1 (Fig. 1.8f). The slow activation of CN in AGPVMs compared to NRVMs as quantified by t1/2 and the combined computational/experimental methodology that proposed low CaMfree levels as the culprit for the alternate response in AGPVMs, hint at a potential mechanism by which cardiomyocytes can modulate CN/NFAT dependent physiological and pathophysiological hypertrophic response (Fig. 2.26). This is consistent with the incident of massive hypertrophy in a mouse model overexpressing CaM in the heart (), and the responsiveness of the genetically encoded sensor of CaMfree, (BsCaMIQ) only in the presence of overexpressed CaMWT in adult rabbit ventricular myocytes (). Accordingly, any pathological perturbations in ambient CaM levels is predicted and expected to influence CN dynamics. 


Figure 2.25 CN Activation Parameters in NRVM versus AGPVMs. (a) the mean value of t1/2 (time to half- maximal activation amplitude) in NRVM and AGPVMs paced at 1 Hz. The data for DuoCalN (Duo)  and UniCalN (Uni) is plotted. The value in NRVMs is about 2s, 5- fold faster than that of AGPVMs (~10s). (b) The mean value for the slope of the normalized sensor amplitude versus pacing frequency (Fig. 2.17, Fig. 2.18 and Fig. 2.20, Fig. 2.21) illustrating stark difference between AGPVMs (value of ~0.05) and NRVMs (~0). (c) Computational estimate of   mean [CaM]free values (~10 cells) (Eq.17, parameter C1 in the mathematical model) in NRVMs (~250 nM) versus AGPVMs (~100 nM) based on the fitting of the mathematical model to the pacing induced DuoCalN FRET response (Fig. 2.22 and Fig. 2.23).  

In recent experiments by Yang et al.   ADDIN EN.CITE (), FRET measurements were employed to demonstrate  that 90% of the z-line CaM in adult myocyte was RyR2-bound, and, that the binding affinity was decreased by 3-fold in a post- myocardial rat infarction heart failure model  ADDIN EN.CITE (). Combining with the empirical and mathematical insights obtained by the sensors developed in this section, this would imply that failing myocytes have higher free CaM levels, and accordingly are more prone to CN activation. This ’free CaM’ conjecture developed here can be experimentally tested by co- expressing CaMWT in AGPVMs alongside the sensor and mCherry-NFAT to investigate concurrent activation of CN and NFAT in response to elevated CaM levels.




Figure 2.26 Maturation and Adult Hypertrophy and CN Dynamics. Ca flux from calcium channels activates CaM that in turn bind and activate CN complex. In neonatal heart kinetics of CN activation is fast and free CaM level is high so that CN is prone to activation and hypertrophic genes are on. In adult heart, CN kinetic is slow and free CaM level is low. CN is less prone to activation. CN activation in adult heart leads to pathological hypertrophy.

Conclusion
In chapter 1, we carried out scanning alanine mutagenesis of the whole IQ domain of CaV1.3 channels, and challenged the prevailing IQ centric model of CDI induction in calcium channels. An alternative model of CaM regulation ‘CaM departure model’ emerged from our whole- cell patch clamp and quantitative live cell FRET- binding assays (Fig. 1.4). By applying these insights to naturally RNA- editing variants of CaV1.3 channels, we discovered a surprising role for apoCaM preassociation in modulating the CDI of these channels. Moreover, apoCaM modulation of the CDI offered a mechanism by which the ambient CaM fluctuations could tune CDI in the brain much like switches on a rheostat. 
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